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ABSTRACT 
 
Objective. The interaction between human immunodeficiency virus (HIV) and human 
papillomavirus (HPV) results in an increased burden of cervical cancer among HIV-
positive women. This research aims to shed light on the important topic of HIV/HPV co-
infection with the goal of informing HPV disease prevention efforts. Specifically, using 
longitudinal data we estimated the natural history of HPV and cervical cancer among 
HIV-positive women to inform cost-effectiveness modeling aimed at identifying optimal 
targeted prevention approaches for this high-risk population. 
Methods. In total 1,277 women (45% positive for HIV-1 and/or HIV-2) were 
followed for an average of two years in Senegal, West Africa between 1994 and 2010. 
Cytology and HPV DNA testing were performed at approximately 4-month intervals. 
Competing risk modeling was used to estimate rates for transitioning between three 
clinical relevant natural history stages (Normal, HPV, and HSIL) for HIV-positive and 
HIV-negative women separately. Markov cohort modeling was used to simulate the 
impact of various cervical cancer screening strategies among HIV-positive women. 
Specifically, we compared the relative cost-effectiveness of six screening strategies 
(Hybrid Capture 2 HPV testing, rapid HPV testing, cytology, visual inspection with 
acetic acid (VIA), HPV testing followed by cytology triage, and HPV testing followed by 
VIA triage) and five screening frequencies using projected life expectancy and 
incremental cost-effectiveness ratios (ICER). Further, the potential cost-effectiveness of 
HPV vaccination at the time of HIV diagnosis was simulated under various theoretical 
effectiveness scenarios. One-way and probabilistic sensitivity analyses were conducted to 
explore the impact of uncertainty on results. 
Results. HIV-positive women had significantly higher rates of progression and lower 
rates of regression compared to HIV-negative women (i.e. adverse transitions). Among 
those with HIV infection with multiple HPV types, HPV-16/18, HIV-1, and CD4+ count 
<200 were associated with adverse transitions. Across a broad range of screening 
scenarios, VIA was identified as the most cost-effective and contextually feasible 
screening approach. Compared to no screening, annual VIA resulted in an average 
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discounted increased life expectancy of 1.7 months and a 40% reduction in cervical 
cancer incidence with an ICER of I$1,500 per life year saved. High underlying HPV 
prevalence among HIV-positive women significantly reduced the cost-effectiveness of 
HPV testing. HPV vaccination was only cost-effective under optimal vaccine efficacy 
and/or costing scenarios. Specifically, with costs ≥I$31 vaccination became dominated 
when vaccine efficacy fell below approximately 70% and 40% for reducing transitions 
from Normal to HPV-16/18 and HPV-Other states, respectively. 
Conclusions. High rates of adverse transitions indicate that targeted screening for the 
growing population of HIV-positive women in Africa is needed. Based on World Health 
Organization criterion for cost-effectiveness, targeted VIA screening represents an 
important prevention opportunity among this high-risk population. With lower vaccine-
induced titer levels reported among adult HIV-positive women and a potential 
corresponding reduction in vaccine efficacy, HPV vaccination costs must be reduced for 
primary prevention to be cost-effective in comparison to screening. Efforts to implement 
targeted screening, reduce vaccine costs, develop therapeutic vaccines, and evaluate 
upcoming HPV antiviral treatments should be made. 
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A. DISSERTATION OVERVIEW 
 
A.1 Public Health Challenge 
Human papillomavirus (HPV) disproportionately affects women who are seropositive 
for human immunodeficiency virus (HIV), despite advances in and increased access to 
HIV treatment. Significant efforts have been made to better understand the complex 
relationship between HPV and HIV in order to reduce HPV associated morbidity and 
mortality among HIV-positive women; however, much remains unknown. This research 
aims to shed light on the important topic of HIV/HPV co-infection with the express goal 
of informing HPV disease prevention efforts. 
The following research is based on three key converging areas of science. First, over 
the past two decades a series of National Cancer Institute funded studies in Senegal, 
Africa have examined the impact of cervical HPV infection among HIV-negative and 
HIV-positive participants. Collectively this research, in concert with other studies 
conducted throughout the world, has established that cervical HPV infection 
disproportionately affects women who are HIV-positive. Specifically, HIV-positive 
women are at increased risk for acquiring cervical HPV and are more likely to have 
persistent infections which progress to dysplasia and invasive cervical cancer. Second, 
several key articles published in the past decade have demonstrated that early initiation 
and continuous use of highly active anti-retroviral therapy (ART) significantly reduces 
the morbidity and mortality associated with HIV. However, the impact of ART on HPV-
associated disease remains unclear. While ART significantly reduces other opportunistic 
infections, research currently indicates that risk of cervical cancer appears to be largely 
unaffected by ART use. Further, ART increases life expectancy providing additional time 
to acquire and develop HPV-associated disease which may lead to actual increases in 
cervical cancer among HIV-positive women. Third, cervical cancer prevention programs 
(namely, vaccination and screening) are not generally available in sub-Saharan Africa 
(SSA). Part of the barrier to implementation of prevention programs is that the most 
effective and comprehensive strategy for HIV-positive women living in SSA remains 
unknown. 
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A.2 Specific Aims 
Using data previously collected as part of a series of studies in Senegal the following 
research questions were examined: 
 
Manuscript I: What is the natural history of cervical HPV infection (i.e. the probability 
of transitioning between key states of the natural history) among women who are HIV-
positive, and how does this compare to women who are HIV-negative? 
Aim: Quantitatively summarize and compare the natural history of cervical HPV 
infection among HIV-negative and HIV-positive women (e.g. the risk of HPV 
acquisition, and development and duration of various stages of clinical disease). 
 
Manuscript II: What is the optimal cervical cancer screening strategy for HIV-positive 
women in sub-Saharan Africa in the era of ART?  
Aim: Identify optimal cervical cancer screening strategies for HIV-positive 
women living in Senegal using cost-effectiveness modeling.  
 
Manuscript III: What is the potential impact of HPV vaccination when applied to HIV-
positive women in Senegal? Specifically, under what circumstances (if any) does the 
HPV vaccine yield meaningful benefits among HIV-positive women? 
Aim: Explore the potential impact of the HPV vaccine when applied to HIV-
positive women in Senegal (varying efficacy and cost). 
 
These aims collectively serve to identify optimal cervical cancer prevention strategies 
among the high-risk population of HIV-positive women. Results can be used to directly 
inform public health policy for reducing HPV-associated morbidity and mortality in 
Senegal, with potential application to the broader area of SSA. 
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B. GENERAL BACKGROUND 
 General literature related to this research is summarized below followed by focused 
literature reviews presented before each manuscript (in Chapters C, D, and E). 
 
B1. Senegal: Brief Contextual Background 
This research is based on longitudinal data collected in Senegal, a small West African 
country externally bounded by the Atlantic Ocean. The majority of data collection 
occurred in Dakar, the capital of Senegal. Senegal has a population of roughly 14 million, 
of which 60% reside in rural areas and 94% identify as Islamic [1]. Approximately, one 
in three married women is in a polygamous relationship [2-4]. Senegal receives millions 
of dollars of international aid each year to invest in healthcare services, as well as 
sustainable agriculture and renewable energy. Average life expectancy is estimated as 60 
years for both men and women [1]. In 2007 it was estimated that unemployment was 
48%, with 54% of the population living below poverty [1]. The 2013 gross national 
product (GNP) per capita for Senegal was $1,050 (for reference Sudan has a GNP of 
$1,750) [5]. In 2008, there was one physician for every 20,000 people [6].  
  
B2. Human Papillomavirus 
B2.1 Epidemiology and pathogenesis of genital HPV 
Human papillomavirus (HPV) is one of the most common sexually transmitted 
infections in the world [7], and is the necessary cause of genital warts and squamous 
cervical cancer [8-12]. The cervix is the lower, narrow portion of the uterus that connects 
the body of the uterus with the top of the vagina or birth canal (Figure 1). Additionally, a 
number of other potentially life-threatening sequelae result from HPV infection, 
including cancers of the anus, head and neck, penis, vulva, and vagina, as well as 
recurrent respiratory papillomatosis [13]. In total, it is estimated that 5.2% of cancers 
diagnosed worldwide are attributable to HPV [14]. For reference, it is estimated that 
roughly 16.1% of cancers are attributable to infectious agents and 19% of cancers are 
attributable to smoking [15, 16]. There are over 100 different types of HPV, of which 
over 40 infect the genital area [17]. HPV types differ in terms of the type of epithelium 
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they infect, their ability to evade immune detection, resist immune defenses, and their 
oncogenic effects. Types are hierarchically categorized based on their oncogenic 
potential: high-risk (HR-HPV) and low-risk (LR-HPV). High-risk types 16 and 18 
collectively account for roughly 70% of HPV-related cancers worldwide [11, 12, 18]. 
There is evidence of geographical variability in the prevalence of HPV infection. For 
instance, based on data extracted from 194 studies with a cumulative sample of over one 
million women with normal cytology, the prevalence of HPV infection in women was 
19.6% in West Africa compared to the world average of 11.7% [7, 19]. Notably, these are 
estimates, the veracity of which depends on the methods used to detect HPV and 
representativeness of the women sampled. There may also be some degree of geographic 
variability in the distribution of HPV types (although the majority of cervical cancer is 
attributable to types 16 and 18 throughout the world) [9]. 
The primary route of genital HPV transmission is sexual contact [20]. Based on 
epidemiological evidence, genital HPV is thought to be highly transmissible; however, 
empirical data on transmission are limited [21, 22]. Notably, the prevalence of HR-HPV 
is consistently higher then LR-HPV [20, 23]. Previously, this pattern was thought to be 
entirely due to differences in duration of infection as HR-HPV types are more persistent 
[23, 24]. However, HR-16 is consistently shown to have the highest incidence compared 
to other types [25, 26]. Similarly, estimates of the incidence of HR-18 are high, although 
less consistently so [25]. These patterns suggest possible differences in transmission by 
HPV type. 
Cervical HPV infection occurs in the basal cells of the stratified epithelium (the only 
cells in which the HPV virus can replicate) [27]. The virus infects epithelial tissues 
through micro-abrasions that expose segments of the basement membrane of the cervix. 
The HPV viral genome is transported to the nucleus of a basal cell by unknown 
mechanisms. A complex transcriptional cascade then occurs as the host cell begins to 
divide and become decreasingly differentiated in the upper layers of the epithelium. 
These host cells release copies of HPV, facilitating further spread of the virus. Pre-
cancerous lesions are classified by two schemes: the Bethesda system differentiates 
between low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, 
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respectively), while the Richart system differentiates between cervical intraepithelial 
(CIN) grades 1, 2, and 3 (Figure 2). Both are used to indicate the progressive nature of 
pre-cancerous lesions, with invasive cervical cancer occurring when poorly differentiated 
cells break through the dermis of the cervix. 
The vast majority of genital HPV infections are asymptomatic, transient, and 
naturally resolve without treatment [25]. The average length of HPV infection has been 
estimated to be roughly seven months for men (penile infection) and eight months for 
women (cervicovaginal infection) [24, 28], although there is evidence that the duration of 
penile infections may be even shorter [29]. Worldwide, the prevalence of genital HPV 
infection peaks between age 20 and 30 [20, 23, 25]. Co-infection with multiple HPV 
types is common; however, estimates for the prevalence of co-infection vary considerably 
[30-32]. In those cases in which genital HPV infection does not naturally resolve, pre-
cancerous cervical lesions may develop, and if left untreated, can subsequently progress 
to cervical cancer. The squamocolumnar junction is the area in which cervical cancer is 
most likely to develop (Figure 1). Cervical cancer may take up to 25 years to develop 
after HPV infection, leaving a large time period in which to intervene (Figure 3) [33].  
 
B2.2 Genital HPV clearance and acquired immunity 
Infections can clear completely; however, they may also remain latent but capable of 
reactivation [34-36]. There is evidence that risk of acquiring a new HPV infection is 
independent of prior infection with other types (including prior infection with other 
phylogenetically related types) [37]. However, it has been shown that prior HPV 
infection may protect against future infection with the same HPV type, although the 
duration and mechanisms of immunity remain unclear [38]. Research efforts aimed at 
resolving these important issues are hindered by the lack of a correlate for immunity. 
Essentially, the presence of detectable antibodies does not necessarily equate to acquired 
functional immunity and the lack of detectable antibodies does not necessarily equate to 
the absence of prior exposure [39]. In short, while there is evidence of acquired type 
specific natural immunity, the proportion of women who developed immunity remains 
unknown, as well as the extent and duration of the protection afforded. 
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B2.3 Prophylactic HPV vaccines 
There are currently three prophylactic HPV vaccines available: a bivalent vaccine 
(Cervarix/HPV2) which protects against types 16 and 18, a quadrivalent vaccine 
(Gardasil4/HPV4) which protects against types 6, 11, 16 and 18, and a nonavalent 
vaccine (Gardasil9/HPV9) which protects against 16, 18, 31, 33, 45, 52, 58, 6, and 11. 
HPV2 and HPV4 protect against those types that cause approximately 70% of cervical 
cancer, while HPV9 protects against those types that collectively cause approximately 
90% of cervical cancer [9, 11, 40]. More than 99% of people develop an antibody 
response to those types included in the respective vaccines [41-43]. Notably, the antibody 
response to the vaccine is higher than that resulting from natural infection [41]. This is 
unusual as vaccine induced immune responses are typically less than that incurred 
through natural infection.  
As there is no known serologic correlate of immunity, phase II and III clinical trials 
conducted in the United States (US) used observed HPV-vaccine type-related incident 
infection and cervical dysplasia as primary outcomes to determine efficacy. Vaccines 
have been found to be highly efficacious in preventing HPV-vaccine type-related 
persistent infection (in males and females) and dysplasia (pre-cancerous lesions in 
females). Efficacy against HPV vaccine-type related CIN2/3 was found to be 93% for 
HPV2, 98% for HPV4, and >98% for HPV9 [43-45]. Importantly, HPV2 and HPV4 
vaccines induce some cross-protection against certain HPV types that are 
phylogenetically related to those types included in the vaccine [46-50]. Cross-protection 
has not been observed in early HPV9 trials [43]. HPV vaccines do not have demonstrated 
therapeutic benefit in treating existing lesions, although there is evidence suggesting that 
there are some protective effects among those with prior but not current infection (i.e. 
HPV seropositive but HPV DNA negative). For instance, in the PATRICIA trial vaccine 
efficacy for the prevention of HSIL in women with no evidence of current or prior HPV-
16/18 infection was 94.6%, compared to 68.8% in women with evidence of prior HPV-
16/18 infection [50]. The duration of protection afforded by the vaccines remains 
unknown. A subsample of participants from phase III clinical trials have been followed 
for up to 8.5 years with no evidence of waning immunity [51].  
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Based on evidence that the HPV vaccines are safe and immunogenic among HIV-
positive patients the Advisory Committee on Immunization Practices (ACIP) currently 
recommends HPV vaccination for HIV-positive females and males up to the age of 26 in 
the US [52-54]. However, the efficacy and duration of immunity afforded by vaccination 
when applied to the HIV-positive population remains unknown (both for those who are 
vaccinated prior to becoming HIV-positive and those who are vaccinated while HIV-
positive), although several efficacy trials are currently underway [55]. The relative 
benefit of vaccinating HIV-positive women remains unknown given a multitude of 
competing health risks, as well as limited resources in nations with high HIV endemicity. 
Due to these gaps in the literature, international recommendations regarding HPV 
vaccination among those who are HIV-positive have not been made. 
Importantly, HPV vaccination is the most expensive publically funded vaccine; 
therefore, it is cost-prohibitive for many countries to implement mass vaccination 
campaigns and there is growing need to examine potential targeted vaccination strategies. 
As the 3-dose vaccine series is costly and involves multiple clinic visits over the course 
of six months there is also growing interest in exploring the potential to adopt a 2-dose 
schedule. Recent clinical trials have found that antibody responses in females were non-
inferior up to two years after receiving a 2-dose series compared a 3-dose series [56, 57]. 
However, one study found that after two years of follow-up girls who received a 2-dose 
series experienced type-specific waning of immunity [56]. Given inconsistent evidence, 
further research examining the potential application of a 2-dose series is underway as the 
economic implications are considerable. 
 
B3. Cervical Cancer 
B3.1 Epidemiology of cervical cancer 
Cervical cancer is the third most commonly diagnosed cancer and the fourth leading 
cause of cancer death in women worldwide, with an estimated 528,000 new cases and 
266,000 deaths in 2012 [58]. Cervical cancer disproportionately impacts low resource 
nations. For instance, approximately 88% of cervical cancer mortality occurs in low-
resource countries which have only 5% of global cancer resources [59, 60]. It is estimated 
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that cervical cancer represents approximately 35% of cancers among Senegalese women 
[61]. Of cancers that affect women, cervical cancer results in the most years of life 
expectancy lost (estimated at 29 years per person among HIV-negative women) [62].  
The morbidity and mortality associated with cervical cancer can be drastically 
reduced with the widespread implementation of routine screening as demonstrated in the 
US. Between 1955 and 1992, cervical cancer incidence and death rates declined by more 
than 60% due to routine Papanicolaou tests (cervical cytology) [63]. Of those cases that 
occur, it is estimated that 56% are among women who had never been screened or had 
not been screened in the 3 years prior to diagnosis [64]. For context, age-standardized 
mortality rates for cervical cancer are 25.5, 14.5 and 1.7 for Senegal, South Africa, and 
the US respectively. In Senegal, cervical survival is roughly 33.6% (compared to 69% in 
the United States) [61]. There are four stages of cervical cancer (I-IV). Staging is based 
on the size of the cancerous growth, the location of the growth in the cervix, and the 
presence of metastatic tumors.  
 
B4. Human Immunodeficiency Virus  
B4.1 Epidemiology and pathogenesis of HIV 
Today there are more than 35 million people living with HIV/AIDS of whom 70% are 
in sub-Saharan Africa (1 in 20 adults in SSA are HIV-positive), and 50% are women 
[65]. There are two types of HIV: HIV-1 and HIV-2. Worldwide, the predominant virus 
is HIV-1, while the relatively uncommon HIV-2 is concentrated in West Africa. HIV-2 is 
considered to be a more mild type with a longer incubation period and lower 
transmissibility [66]. Recent data indicates that HIV-2 is slowly dying out, likely due to 
lower transmissibility and relative geographic isolation. A trend analysis based on 10,321 
women in Senegal found that the relative prevalence of HIV-2 dropped from 54.2% in 
1990 to 20.9% in 2009 [67]. For each HIV type, additional sub-classifications exist with 
slight variations in transmissibility, incubation periods, viral loads, death rates, and 
responsiveness to treatment [66]. HIV is one of the most variable of human pathogens 
with 800 distinct genome sequences; thus, it quickly mutates and diversifies within hosts 
[68]. HIV has such great genetic instability that HIV virus particles within a person are 
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considered to be a “swarm of highly related but non-identical viral genomes termed 
quasi-species” (page S8) [68]. 
HIV is distinct in that the direct target of the infection is the immune system itself. At 
the micro-level, the virus infects human T-lymphocyte cells which are responsible for 
cell-mediated immune function. T-lymphocytes have a series of CD4+ protein molecules 
on their surface. HIV particles lock onto CD4+ protein sites through the gp120 molecule 
which acts like an arm. Once locked onto a CD4+ protein site, the gp41 molecule (a 
second, harpoon-like arm) pierces the T-lymphocyte. Cell invasion occurs during which 
HIV genetic codes are absorbed into the T-lymphocyte cell. Essentially, the cell is 
hijacked and used as a replication facility for the virus. The host T-lymphocyte cell 
begins to disintegrate and die, with the new HIV particles released into surrounding blood 
and tissue to eventually repeat the process. Over the course of years, the virus depletes 
CD4+ T-lymphocytes and opportunistic infections (OIs) arise. OIs are defined as 
infections that are more frequent or severe as a result of immunosuppression. OIs 
capitalize on the suppressed immune system, and represent the principal cause of 
morbidity and mortality for HIV-positive people. 
B4.2 Antiretroviral therapy: guidelines, access, and impact 
In 1996 a new form of HIV treatment was introduced, broadly termed highly active 
anti-retroviral therapy (ART). ART is much more effective than previous treatment 
strategies in reducing the HIV-associated morbidity and mortality as it diminishes HIV 
viral loads which subsequently results in improved CD4+ counts and immune 
reconstitution. Successful treatment has led to profound reductions in OIs. Further, as 
ART significantly reduces viral loads (to the point that patients may have undetectable 
levels) risk of HIV transmission is significantly reduced [69-71]. However, some 
research indicates that the use of ART is associated with increased sexual risk behaviors 
[72-76]. Thus, there remains uncertainty regarding the actual effect of ART on 
transmission at the population level. 
There was growing evidence supporting early initiation of ART (prior to CD4+ 
counts falling below350 cell/µL) [77]. For instance, uncontrolled viral replication and 
chronic inflammation resulting from infection have been found to increase risk of HIV 
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transmission and contribute to the development of serious non-AIDS events (such as 
cardiovascular disease and various cancers). Early treatment has been shown to reduce 
both HIV transmission and the development of serious non-AIDS conditions [77, 78]. 
Additionally, evidence suggests that although CD4+ recovery may occur on treatment, 
complete functional recovery may not be achieved [79]. This is likely due to the fact that 
CD4+ count is one indicator of a complex immune system function. Updated World 
Health Organization (WHO) treatment guidelines recommend initiating ART when 
CD4+ cell counts drop below 500 cell/µL [80]. After initial treatment, continuous ART 
use is recommended regardless of CD4+ count [81]. 
B4.3 Epidemiology of HIV in Senegal 
Senegal has one of the lowest rates of HIV in Africa, as 1% of those aged 15-49 are 
HIV seropositive [82]. However, the prevalence of HIV among sex workers, men who 
have sex with men, and injection drug users was recently estimated to be 20%, 22% and 
10% respectively, demonstrating that distinct sub-groups are disproportionately at risk of 
acquiring HIV [83]. Additionally, there are some geographical differences in HIV 
prevalence within Senegal, with those areas surrounding Gambia (a country nested within 
Senegal) disproportionately impacted by HIV. Importantly, the Senegalese government 
was one of the first in Africa to formally acknowledge HIV and implement an active 
response to the epidemic. Due to these efforts, HIV incidence has stabilized in the past 
decade with roughly 2,000 new cases per year and a total of 40,000 prevalent cases [82]. 
The WHO estimates that 50-56% of those who are HIV-positive have access to ART 
therapy (CD4 < 350) in Senegal; above the average for SSA at 37% [82, 84]. This 
represents a large increase in access over the last decade, partially due to concerted 
efforts to increase the number of physicians qualified to administer anti-retroviral 
medication. For instance, in 2001 there were 12 physicians qualified to administer ART, 
this increased eight-fold to 95 in 2005 [85]. However, access to ART alone does not 
equate to uptake and adherence, important factors necessary for reducing HIV-associated 
morbidity and mortality. 
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B4.4 HIV and the development of cancer 
Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical cancer are AIDS-defining 
events (ADEs). ADEs are those clinical events that signal a change in the health status of 
an HIV-positive individual (particularly with respect to survival). ADEs are used to 
define the clinical presentation of AIDS in combination with CD4+ count. Importantly, 
those with HIV are at increased risk of many types of cancer in comparison to the general 
population [86]. Although it remains unclear whether HIV is itself directly oncogenic, it 
is hypothesized to contribute to the development of malignancies through several 
mechanisms (e.g., chronic inflammation, infection by oncogenic viruses, impaired 
immune surveillance, imbalances between cellular proliferation and differentiation). 
Incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphoma have declined in the era of 
ART; however, risk of cervical cancer and several non-AIDS defining cancers (e.g. 
cancers of the lung, liver, anus, lip, mouth, pharynx, and skin, as well as Hodgkin 
lymphoma) have either remained unaffected by ART or increased likely due to extended 
life expectancy and complex interactions between HIV, immune function, and adverse 
responses to ART [87-89]. 
 
B5. HPV/HIV Co-infection 
B5.1 Overview 
There is significant evidence of a synergistic interaction between HIV and HPV, 
resulting in high HPV-related morbidity and mortality among HIV-positive populations 
[90]. There are two main theoretical explanations for this interaction [91]. The first 
explanation maintains that HIV causes systemic immune dysfunction, such that it is 
incapable of detecting and/or responding to new HPV infections (importantly, this may 
also lead to the reactivation of latent HPV infections). The second explanation maintains 
that HIV actually enhances HPV infection by interacting with HPV infected cells. To 
date, there is evidence to support both of these theories and there is no clear prevailing 
etiological explanation for this interaction.  
HIV-positive women are at increased risk of HPV infection when compared to the 
general population [3, 92, 93]. For instance, one study found that among HIV-positive 
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women the odds of developing incident HPV detection were 8.8 times greater than in 
HIV-negative women [94]. HIV-positive women are more likely to be infected with 
multiple HPV-types [95-98]. For instance, among 148 South African HIV-positive 
women, 80% were infected with multiple oncogenic HPV types [97]. Infection with 
multiple types may be due to the fact that HIV-positive women experience more 
persistent infection (meaning the infection is less likely to clear and the duration of the 
infection is therefore longer) [92, 99, 100]. This provides additional time for clinical 
disease to develop and to transmit the infection. Some studies have found that HIV-
positive women have higher HPV viral loads then the general population [93, 101, 102]. 
The biological mechanism for this remains unclear, but higher viral load is hypothesized 
to lead to higher transmissibility and extended duration of infection. Overall, studies have 
shown that HIV-positive women are 1.5 to 8 times more likely to have cervical cancer 
than HIV-negative women [3, 88, 103-106]. Further, cervical cancer has been observed to 
occur at an earlier age among HIV-positive women. For instance, in South Africa the 
mean age at time of diagnosis was 55.2 and 39.8 years for HIV-negative and HIV-
positive women respectively [107]. HIV-positive women are also more likely to present 
with more advanced cancer, particularly when CD4+ count are below 200 [108, 109].  
B5.2 The Role of ART, CD4+ count, HIV viral load, age, and HPV type 
With the introduction of ART, the morbidity and mortality associated with many 
opportunistic infections (OIs) has been greatly reduced. However, for reasons that remain 
unclear, HPV continues to disproportionately affect those who are receiving treatment 
[90, 103, 110]. At the population level, ART does not appear to reduce incidence of 
cervical cancer among those who are HIV-positive [88, 106, 111, 112]. However, some 
observational studies have demonstrated protective effects of ART during earlier stages 
of HPV natural history, namely with regard to decreased incident pre-cancerous lesions 
and increased regression [113-118]. For instance, Ahdieh-Grant et al. found that among a 
cohort of 312 HIV-positive women incident regression increased over time after ART 
initiation (ptrend = 0.002) [113]. Nonetheless, the authors note that the majority of cervical 
lesions among HIV-positive women did not regress to normal during follow-up, even 
among those on ART. Similarly, among 714 HIV-positive women, those on ART were 
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40% more likely to have observed regression from pre-cancerous lesions (after 
adjustment for CD4+ count) [116].  
The fact that ART appears to have little, if any, impact on cervical cancer is 
illustrative of a recent paradigm shift regarding OIs. In the past, OIs were thought to 
occur only after the immune system was significantly impaired. With the introduction of 
ART, it was hypothesized that OIs would become rare as treatment restored immune 
function. However, research on meningitis, tuberculosis, and HPV indicate that some OIs 
establish themselves far earlier in the natural history of HIV. In the case of HPV, this 
observation is somewhat intuitive as the virus is naturally capable of evading the immune 
system even among those who are HIV-negative. In other words, immune suppression is 
not necessary for the development of cervical cancer, but an impaired immune system 
does lead to increased risk and earlier development of cervical cancer. There are two 
broad explanations for the presence of OIs early in the natural history of HIV infection 
(which are not mutually exclusive). First, there are biological interactions between some 
OIs and HIV which have yet to be fully understood. Second, CD4+ count is an imperfect 
surrogate for immune function. While CD4+ count may be high early in the natural 
history of HIV (or due to ART) there could be additional indices of immune function that 
are impaired. 
The effect of CD4+ count (independent of ART) on the natural history of HPV 
appears to be complicated and not yet fully understood. Overall CD4+ count appears to 
be inversely associated with HPV prevalence, persistence, and pre-cancerous lesions [3, 
112, 119-122]. For instance, Delmas et al. found that among 485 HIV-positive women, 
those with CD4+ counts <200 had approximately twice the prevalence and incidence of 
pre-cancerous lesions compared to women with CD4+ counts > 500 [119]. Similarly, in a 
cohort study of 774 HIV-positive women followed for 5.5 years it was shown that 
incidence of pre-cancerous lesions and risk of progression were greater for those with 
CD4+ < 500 [112]. Notably, in this study ART was not independently associated with 
incidence outcomes. Some research has indicated that progression from pre-cancerous 
lesions to anogenital cancer is independent of CD4+ count [123, 124]. Evidence that 
women with high CD4+ counts remain at increased risk to HPV infection (compared to 
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HIV-negative women) may indicate that HIV directly interacts with HPV. This would 
support the theory that there is a synergist interaction between these two agents. 
However, CD4+ count may simply be an incomplete measure of immune function. 
HIV plasma viral load is the least understood of these factors and warrants additional 
research. Several studies have shown a positive association between HIV viral load and 
the development of clinical HPV-related disease [3, 122, 125, 126]. For instance, among 
a cohort of 627 women in Senegal, Hawes et al. found a significant positive association 
between HIV viral load and the development of high-grade squamous intraepithelial 
lesions (HSIL) [122]. This association was not significant after adjustment for CD4 
count. Based on longitudinal data with over 1,800 HIV-positive women, Strickler et al. 
found evidence of a positive interaction between HIV viral load and HPV infection [126]. 
Using data from the AIDS Clinical Trials Group, a simulation model aimed at identifying 
the population level impact of ART found that HIV viral load was marginally associated 
with prevalent HPV infection (independent of CD4 count) [127]. As HIV viral load is 
inversely related to CD4+ count, any association between viral load and HPV-related 
cervical disease simply underscores the importance of ART. 
There may be differences in the distribution of HPV types when comparing HIV-
positive and HIV-negative women. For instance, a study of approximately 1,200 women 
in India found that HPV 18 and 16 were the predominant types among all women with 
prevalent infection; however, among HIV-positive women 53% of oncogenic HPV 
infections were from types other than 16 and 18 [128]. Differences in the distribution of 
HPV types have been demonstrated at various stages of clinical cervical disease as well. 
Based on a meta-analysis of 20 studies throughout the world Clifford et al. found that 
among women with HSIL, HPV-16 was less common in HIV-positive women, and types 
considered to be low-risk were more common (Figure 4) [96]. Notably, HIV-positive 
women were far more likely to be infected with multiple HPV types then HIV-negative 
women (41.4% verse 6.7% respectively) [96]. Thus, distributional differences may be 
driven by the increased prevalence of infection with multiple types, and it unknown 
which type(s) actually caused the development of HSIL. Additionally, based on the 
analysis of 164 cervical cancer cases in two SSA countries, it was found that type 16 was 
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less frequent than reports in the rest of the world (49.4% vs. 62.6%), and 18 and 45 were 
roughly two times more frequent (19.3% vs. 9.4% and 10.3% vs. 5.6% respectively) 
[129]. Based on this ecological study, the authors of the study posit that the high 
prevalence of HIV in SSA may drive these geographic HPV type distributional 
differences. Notably, some research indicates that HIV-negative and HIV-positive 
populations have similar distributions of HPV [130]. In summary, findings are 
inconsistent and based on studies which have important methodological limitations. Thus, 
it is unknown what impact any distributional differences have on HPV-related disease 
among those who are HIV-positive. Nonetheless, implications in terms of vaccine 
effectiveness could be profound as vaccines are type specific. 
In HIV-negative populations, prevalence of HPV is strongly dependent on age 
(peaking in the early 20’s) which is primarily due to age-related sexual behaviors and 
acquired immunity. Importantly, data suggests that age is not as strongly associated with 
HPV prevalence among HIV-positive women, likely due to increased persistence, 
infection with multiple types, and sexual practices in SSA. For instance, in a cross-
sectional study of 498 HIV-positive women in Kenya (age 18 to 55), HR-HPV positivity 
did not vary significantly by age [118]. Further, based on an analysis of 282 HIV-positive 
in Cameroon (age 19 to 68), Atashili et al, found that women aged 26 to 59 tended to 
have a slightly higher prevalence of cervical pre-cancerous lesions than other women, 
although this was notably non-significant [131]. Among women with CD4+ counts >200, 
there were no prevalence differences by age. The authors of this study posit that there is 
little value to age-targeted screening among HIV-positive women. 
 
B6. Decision Modeling: Methodology, Application and Impact 
B6.1 Decision modeling in epidemiology 
Decision modeling is broadly used to compare the advantages and disadvantages of 
various policies or interventions. It is undertaken to inform decision-making and/or 
identify gaps in knowledge that merit future research initiatives. The application of 
decision modeling to inform public health decision making and future research has grown 
over the past decade. For example, decision modeling has informed the development of 
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vaccination recommendations, cervical screening guidelines, colon cancer screening 
guidelines, environmental regulations, newborn screening practices, consumer product 
standards, strategies for the use of mass media for public health promotion, legal codes 
for smoking detectors, measures to increase the safety of blood transfusions and much 
more. Cost effectiveness analysis (CEA) is a type of decision modeling which provides a 
systematic, quantitative approach for identifying efficient ways to allocate finite 
resources. Both the WHO and the World Bank utilize CEA to prioritize and inform 
practices in resource-limited settings.  
B6.2 Overview of the methodology 
Decision modeling is a mathematical approach to synthesizing scientific knowledge 
regarding a certain process of interest (in this case the natural history of HPV) and is used 
to project key outcomes among a simulated population. In essence, cost-effectiveness 
models incorporate population behaviors and characteristics, disease rates, and other 
factors to simulate at the aggregate level how a given intervention may affect a 
population. Building a deterministic Markov cohort decision model involves four primary 
steps, outlined briefly below. 
1.) Epidemiologic data are synthesized and used as key input data for the model. This 
data is often used to simulate the disease process of interest within a given 
population.  
2.) Based on epidemiological data, the natural disease history for a population is 
simulated by creating ‘states’. States categorize an individual’s status with regard to 
the disease of interest. The model then simulates a fixed cohort passing to and from 
disease states as they age, develop outcomes, or exit the model due to other causes 
(e.g. death). For instance, in models for AIM II and AIM III women transition back 
and forth between four key types of states: uninfected, infected with HPV, various 
stages of HPV-related clinical disease, and death. Synthesized data (from step 1) is 
used to estimate the probability of transitioning between each state for a given time 
interval (referred to as the cycle length).  
3.) Based on the simulated natural history process (from Step 2), key outcomes are 
compared to observed data to ensure consistency with the epidemiologic data (this 
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step is referred to as validation and is used to assess consistency of model outcomes 
with regard to the synthesized data used to construct the model). 
4.) Fourth, key interventions of interest are imposed on the simulated cohort. For 
example, different cervical cancer screening strategies can be simulated and 
compared using this model to project their potential benefits. Strategies are then 
compared to identify the optimal strategy using cost-effectiveness ratios. Briefly, 
cost estimates are based on the financial costs related to screening, diagnosis, and 
treatment. Effectiveness is measured by either life years or quality-adjusted life 
years. The strategies are then ranked in order of cost and compared using an 
incremental cost-effectiveness ratio (ICER). An ICER is calculated using the 
difference in cost divided by the difference in effectiveness, and represents the cost 
of an additional unit of effectiveness (e.g. a year of life) that is obtained when 
implementing a more effective treatment strategy rather than the less effective 
treatment strategy. Strategies that are more costly and less effective than another are 
considered ‘strongly dominated’, while strategies that have higher incremental cost-
effectiveness ratios than the next more effective strategy are consider to be 
‘dominated through extension’. Dominated strategies are not cost-effective relative 
to other interventions.  
Decision modeling allows researchers to: 1) directly compare the effectiveness of various 
interventions; 2) vary when and how often the interventions are used; and 3) vary 
assorted population parameters so that the model can be applied to several distinct 
contextual settings (e.g. the same model can be adapted to identify the best strategy for 
different populations). Conceptually, decision modeling essentially simulates the 
unobserved counter-factual (i.e. using observed data we project the unobserved outcomes 
of various interventions or treatment). Decision modeling can be used to estimate 
outcomes beyond those reported in research studies, provide insight into key gaps in the 
literature, identify factors that drive the cost or effectiveness of various intervention 
strategies, and may be amended as new information emerges. 
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B7. Conclusion 
This research is explicitly directed at informing recommendations for how to best 
reduce HPV-associated morbidity and mortality among HIV-positive women in Senegal. 
Specifically, this research aims to: 1) quantify and compare the natural history of cervical 
HPV infection among HIV-negative and HIV-positive women, 2) use decision modeling 
to identify optimal cervical cancer screening strategies for HIV-positive women, and 3) 
examine the potential impact of targeted HPV vaccination on reducing cervical cancer 
among HIV-positive women. Five primary factors highlight the significance of this 
research. First, in low resource nations cervical cancer is a leading cause of death for 
women. Second, cervical cancer disproportionately affects HIV-positive women. Third, 
HIV is concentrated in SSA. Fourth, cervical cancer among those who are HIV-positive 
may further increase as earlier initiation of ART and improved ART coverage result in 
increased life expectancy. Fifth, cervical cancer is essentially entirely preventable but 
optimal prevention strategies in the context of SSA and among the high-risk population 
of HIV-positive women remain unknown. Collectively, this research is of significant 
applied public health importance and directly addresses several gaps in the literature as 
discussed in further detail in the following chapters. 
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C. MANUSCRIPT I: A Comparison of the Natural History of HPV Infection and 
Cervical Abnormalities HIV-positive and HIV-negative Women in Senegal, Africa 
 
C1. Summary 
Background. There is evidence of an interaction between human immunodeficiency 
virus (HIV) and human papillomavirus (HPV) resulting in increased HPV-associated 
morbidity and cancer mortality among HIV-positive women. This study aims to 
determine how the natural history of cervical HPV infection differs by HIV status.  
Methods. A total of 1,277 women (45% were positive for HIV-1 and/or HIV-2) were 
followed for an average of two years in Senegal, West Africa between 1994 and 2010. 
Cytology (with a sub-sample of histology) and HPV DNA testing were performed at 
approximately 4-month intervals. Competing risk modeling was used to estimate rates for 
transitioning between three natural history stages: Normal, HPV, and HSIL.  
Results. HIV-positive women had significantly higher rates of progression and lower 
rates of regression compared to HIV-negative women (i.e. adverse transitions). Notably, 
HIV-positive women had a 2.57 (95% CI: 1.69-3.91; P < 0.0001) times higher rate of 
progression from HPV to HSIL than HIV-negative women. Among HIV-positive women, 
infection with multiple HPV types, HPV-16/18, HIV-1, and CD4+ count <200 were 
associated with adverse transitions. 
Conclusions. High rates of adverse transitions indicate that targeted screening for the 
growing population of HIV-positive women in Africa is needed. 
 
C2. Background 
Human papillomavirus (HPV) is the necessary cause of squamous cervical cancer 
[132], is highly transmissible, and generally acquired near closely after sexual debut 
[133, 134]. Persistent infection can lead to the development of pre-cancerous lesions 
which, in the absence of treatment or an effective immune response, can progress to 
cancer. Approximately 40 genotypes infect the genital tract and are classified 
hierarchically based on oncogenic potential with high-risk types 16 and 18 accounting for 
roughly 70% of cervical cancer [11]. There is evidence of an interaction between human 
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immunodeficiency virus (HIV) and HPV, with HIV-positive women at increased risk for 
detection of HPV, pre-cancerous cervical lesions, and cervical cancer compared to HIV-
negative women [3, 90-92, 96, 99, 103, 122, 135]. Studies have shown that HIV-positive 
women are 1.5 to 8 times more likely to have cervical cancer than HIV-negative women 
[3, 88, 103-106]. Although there is no definitive etiological explanation for this 
interaction, systemic immunosuppression is likely a contributing factor [91].  
Despite numerous studies describing the increased burden of HPV and cervical 
disease among HIV-positive women, few have longitudinally examined the natural 
history within a single study population and provided direct comparisons to HIV-negative 
women. Thus, estimates for the probability of transitioning between each natural history 
stage (i.e. progression and regression) are limited, as well as our understanding of the 
point at which the natural history of HPV diverges for HIV-positive and HIV-negative 
women. This study was undertaken to estimate and compare the probability of 
transitioning between three clinically relevant natural history stages (Normal, HPV, and 
HSIL) for HIV-positive and HIV-negative women using data from multiple cohort studies 
conducted in Senegal, West Africa.  
 
C3. Materials and Methods 
C3.1 Study population   
 Data from six cohort studies conducted from 1994 to 2010 in Senegal were used for 
the present analysis (Table 2). Protocols for each study have been described elsewhere [3, 
67, 122, 136-141]. All studies screened women age ≥15 presenting at outpatient clinics 
for participation in longitudinal research with HIV testing at baseline, as well as cervical 
cytology and HPV DNA sampling roughly every four months for two years. Recruitment 
occurred at two infectious disease clinics, two family planning clinics, and two sexually 
transmitted disease clinics serving commercial sex workers (CSWs) in or around Dakar. 
Studies were approved by the University of Washington and Senegalese Human Subject 
Review Boards. Consent was obtained from each subject. Data were de-identified and 
shared variables across the six studies were identified and pooled for analysis. 
C3.2 HIV serology and lymphocyte testing 
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Blood samples were tested for antibody to HIV-1 and HIV-2 using an enzyme-linked 
immunosorbent assay (ELISA; Genetic Systems, Seattle, WA, USA) or a microwell plate 
enzyme immunoassay (HIV 1/2 EIA; Sanofi Diagnostics Pasteur, Paris, France). HIV-1 
and HIV-2 infections were distinguished by a peptide-based assay, although the assay 
varied by study (Genie II, Genetic Systems; Multispot, Sanofi Diagnostics Pasteur; 
Immunocomb II, bispot, Orgenics, Yavne, Israel). For HIV-positive women, peripheral 
blood was analyzed with a FACSCount analyzer (Becton Dickinson Biosciences, San 
Jose, CA, USA) to determine number of CD4+ cells per microliter.  
C3.3 Cytologic and histologic testing    
Until 1998 conventional Pap smears were used and evaluated locally in Dakar; 
thereafter, the Thin Prep monolayer cell preparation system (Cytyc Corp., Boxborough, 
MA) was used and evaluated by a cytopathologist in Seattle, USA. Results were 
classified according to the Bethesda system (atypical squamous cells of undetermined 
significance - ASCUS, low-grade squamous intraepithelial lesion - LSIL, high-grade 
squamous intraepithelial lesions - HSIL) [142]. All slides obtained prior to 1998, those 
classified as LSIL or worse, and a random subset of negative slides, were re-read in 
Seattle.  
Protocols for all six parent studies called for colposcopically-directed biopsies and 
treatment for women with evidence of HSIL or invasive cervical cancer (ICC). However, 
subject participation for biopsy/treatment was low in earlier studies, in part, due to delays 
resulting from samples being sent to and re-read in Seattle. With adjustments to study 
practices and improved communication with participants regarding the importance of 
monitoring and treatment, colposcopy follow-up in later studies was vastly improved. 
Representative hemotoxylin-eosin-stained slides were prepared from paraffin-embedded 
biopsy specimens and reviewed by a blinded study cytopathologist. World Health 
Organization pathology criteria and terminology were used to classify specimens [137].  
C3.4 HPV DNA detection and typing 
Polymerase chain reactions (PCRs) assays for detection of HPV DNA were 
performed, although lab methods evolved over time with expansion of type specific 
probes (Table 2). Testing was initially performed by use of HPV L1 consensus primers, 
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HPV type-specific oligonucleotide probes, and a generic probe [143]. This method 
yielded type-specific identification of HPV 6/11, 16, 18, 31/33/35/39, 45/56, and 51/52. 
With new probes available in 1998, HPV detection and typing analyses were performed 
via a PCR-based reverse-line strip test method (Roche Molecular Systems, Alameda, CA) 
with probes for types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 
57, 58, 59, 66, 68, 73, 82, 83, and 84 [144]. In 2000, a Luminex-based testing approach 
was adopted with additional probes for 61, 62, 64, 67, 69, 70, 71, 72, 81, IS39, and 
CP6108 [145]. 
C3.5 Natural history stage classification 
In combination with HPV DNA results, cervical histology was used when available, 
with cytology in all other cases, to classify women at each visit as: Normal (defined as 
HPV-negative), HPV (defined as HPV-positive with one or more type in the absence of 
HSIL), or HSIL (defined as HPV-positive with one or more type with the presence of 
HSIL). Due to a demonstrated lack of reproducibility for cytologic and histologic 
interpretations of low-grade lesions (i.e. ASCUS, LSIL, and CIN1), these results were not 
used to inform stage classifications [146]. As transitions to ICC were not examined due 
to small numbers and possible HSIL treatment effects, these results were excluded. 
C3.6 Statistical analyses 
The natural history of HPV is multi-directional and non-linear such that women may 
transition to any other stage (i.e. participants are at risk of more than one mutually 
exclusive event). Therefore, competing risk modeling was used to estimate cumulative 
incidence functions and the probability of a specific transition over time [147]. To reduce 
the complexities arising from interval censoring, follow-up time was set as the midpoint 
between the visit at which the event of interest or censoring occurred and the preceding 
visit, an approach which has been used previously in infectious disease research [148]. 
For each transition, analyses were conducted up to the point at which the cumulative 
incidence function plateaued and/or there were sparse data. 
At each visit, natural history stage was classified as either incident (i.e. the stage 
differed from the preceding visit) or prevalent (i.e. the baseline visit or the stage was the 
same as the preceding visit). As HPV can be transient, restricting analyses to women with 
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incident classification to eliminate left-censoring can actually produce bias. For example, 
eliminating women who are classified as Normal throughout follow-up (prevalent 
classification), leads to overestimation of the probability of transitioning from Normal to 
HPV as only women with prior HPV detection who become HPV-negative during follow-
up contribute to incident Normal. Thus, to bound results, analyses were calculated 
separately for prevalent and incident natural history stages. To identify factors 
influencing the natural history of HPV among HIV-positive women, the following 
exploratory analyses were conducted: age (≤25 vs. >25), CD4+ count (<200 vs. ≥200), 
HPV type (16/18 vs. others), HIV type (1 vs. 2), and concurrent infection with multiple 
HPV types (>1 vs. 1 type). These analyses were restricted to transitions from Normal and 
HPV due to limited numbers for HSIL. For HPV-16/18 type specific analyses, women 
were classified based on the presence of either one of both of these types [149]. Women 
dually infected with HIV-1 and HIV-2 were removed from HIV type specific analyses 
due to small numbers (n=52). 
Gray’s method was used to test for statistical differences in cumulative incidence 
functions [150]. Robust variances were used when multiple observations from the same 
woman were included when estimating a transition. Schoenfeld residuals were examined 
to assess the proportional hazards assumption. Analyses were conducted using SAS 9.4 
software (SAS Institute, Cary, NC) and STATA 13 software (StataCorp, College Station, 
TX). 
 
C4. Results 
C4.1 Subject characteristics (Table 3)   
Of the 1,277 women, the majority were in their thirties, Muslim, with no more than a 
primary school education. Fifty-percent were married, 40% of whom were in a 
polygamous relationship. Forty-five percent of the sample was HIV-positive, of which 
two-thirds were infected with HIV-1. Antiretroviral therapy (ART) was reported by 27% 
of the HIV-positive sample. Twenty-five percent were classified as having AIDS (defined 
as either a CD4+ count less than 200 (cells/µL) recorded at any point during follow-up or 
an AIDS defining event). Median CD4+ count recorded during follow-up was 416 
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cells/µL. HIV-positive women were slightly less likely to be married, had a lower level 
of education, and were more likely to report using contraception than HIV-negative 
women. HIV-positive women were also more likely to be commercial sex workers 
(CSWs), although this was common in both groups due to recruitment from two clinics 
targeting this population. Most women were followed for over two years, with clinic 
visits approximately every four months. 
C4.2 Progression and regression (Table 4) 
Of 1,054 cases of Normal, 56.4% were incident. HIV-positive Normal women had a 
1.62 times higher rate of HPV detection than HIV-negative women (95% CI: 1.35-1.95). 
The 24-month predicted probability of HPV detection for HIV-positive women was 0.66 
and 0.83 for prevalent and incident classification of Normal, respectively, compared to 
0.49 and 0.67 for HIV-negative women (Figure 5A). Women identified as incident 
Normal had a 1.64 times higher rate of HPV detection than prevalent cases (95% CI: 
1.38-1.95). HIV-positive Normal women also had a 1.60 times higher rate of progression 
to HSIL than HIV-negative women, although this association was not significant (95% 
CI: 0.76-3.36). The 24-month predicted probability of HSIL for HIV-positive women was 
0.04 and 0.07 for prevalent and incident classification of Normal, respectively, compared 
to 0.02 and 0.04 for HIV-negative women (Figure 5B). Women identified as incident 
Normal had a slightly increased rate of progression to HSIL than prevalent cases, 
although this was not significant.  
Of 1,233 cases of HPV detection, 39.7% were incident. HIV-positive women had a 
0.47 times lower rate of regression from HPV to Normal than HIV-negative women (95% 
CI: 0.39-0.56). The 24-month predicted probability of regression to Normal for HIV-
positive women was 0.57 and 0.79 for prevalent and incident HPV detection, 
respectively, compared to 0.83 and 0.96 for HIV-negative women (Figure 5C). Women 
with incident HPV detection had a 1.85 times higher rate of regression to Normal than 
women with prevalent detection (95% CI: 1.58-2.16). HIV-positive women with HPV 
had a 2.57 times higher rate of progression to HSIL than HIV-negative women (95% CI: 
1.69-3.91). The 24-month predicted probability of progression to HSIL for HIV-positive 
women was 0.18 and 0.20 for incident and prevalent HPV detection, respectively, 
  25 
compared to 0.07 and 0.09 for HIV-negative women (Figure 5D). Those with prevalent 
HPV detection had a slightly increased rate of progression to HSIL than incident cases, 
although this was not significant. 
Of 168 cases of HSIL, 62.5% were incident. HIV-positive women had a 0.59 times 
lower rate of regression from HSIL to Normal than HIV-negative women (95% CI: 0.26-
1.65). The 12-month predicted probability of regression to Normal for HIV-positive 
women was 0.10 and 0.14 for prevalent and incident HSIL, respectively, compared to 
0.17 and 0.23 for HIV-negative women (Figure 5E). Women with incident HSIL had a 
1.39 times higher rate of regression to Normal than women with prevalent classification, 
although this association was not significant. HIV-positive and HIV-negative women 
with HSIL had a similar rate of regression to HPV (relative rate = 1.18, 95% CI: 0.78-
1.78). For HIV-positive women the 12-month predicted probability of regression to HPV 
ranged from 0.70 and 0.73 for incident and prevalent HSIL, respectively, compared to 
0.65 and 0.68 for HIV-negative women (Figure 5F). Those with prevalent HSIL had a 
slightly increased rate of regression to HPV than incident cases, although this was not 
significant. 
C4.3 Potential effect modifiers (Table 5)   
HIV-positive women with CD4+ counts <200 had a 3.31 times higher rate of 
transitioning from Normal to HSIL than women with higher CD4+ counts (95% CI: 1.10-
9.93). Low CD4+ count was also associated with a higher rate of progression from HPV 
to HSIL (2.23, 95% CI: 1.27-3.92), and lower rate of regression from HPV to Normal 
(0.54, 95% CI: 0.36-0.81). 
HIV-positive Normal women with HPV-16/18 had a 4.67 times higher rate of 
progression to HSIL than those infected with other HPV types (95% CI: 1.11-19.60). 
Similarly, those with HPV-16/18 infection had a higher rate of progressing from HPV to 
HSIL (2.05, 95% CI: 1.23-3.42) and a lower rate of regression to Normal (0.36, 95% CI: 
0.26-0.49) compared to those infected with other HPV types. HPV type-specific 
differences in associations for the other transitions examined were non-significant. 
HIV-positive women classified as Normal were more likely to transition to HPV with 
the detection of multiple types than a single type (1.99, 95% CI: 1.48-2.69). HIV-positive 
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women Normal were also more likely transition to HSIL with the detection of multiple 
types than a single type, although this association was not statistically significant (2.07, 
95% CI: 0.51-8.45). Further, women with multiple HPV types had a higher rate of 
progression to HSIL (2.29, 95% CI: 1.37-3.84) than those with a single HPV type. HIV-
positive women with multiple HPV types also had a 0.36 times lower rate of regression 
from HPV to Normal than women with a single HPV type (95% CI: 0.26-0.49).  
Among Normal HIV-positive women, those age ≤25 years had a 1.51 times higher 
rate of incident HPV detection than those >25 (95% CI: 1.09-2.08). Age associations for 
the other transitions examined were non-significant. 
Among Normal HIV-positive women, those with HIV-1 had a 1.85 times higher rate 
of incident HPV detection than those with HIV-2 (95% CI: 1.35-2.53). Similarly, women 
with HIV-1 had a 1.83 times higher rate of progression from HPV to HSIL compared to 
women with HIV-2 (95% CI: 0.93-3.59). Women with HIV-1 also had a lower rate of 
regression from HPV to Normal than those with HIV-2 (0.74, 95% CI: 0.56-0.96). In 
contrast, those with HIV-1 had a lower rate of progression from Normal to HSIL (0.41, 
95% CI: 0.16-1.04). Mutual adjustment for baseline age and CD4+ count (as surrogate 
measures of duration and severity of HIV infection), did not affect these findings. 
 
C5. Discussion 
Cervical cancer is the fourth most common cause of cancer death affecting women 
worldwide [58], disproportionately impacting low resource nations (most notably in sub-
Saharan Africa where HIV is endemic) [58, 60]. As HIV-positive women are at increased 
risk of cervical cancer, understanding the distinct natural history within this population is 
essential for informing targeted prevention efforts. This study found that HIV-positive 
women had higher rates of incident HPV detection and progression to HSIL, as well as 
lower rates of regression from HSIL and HPV infection when compared to HIV-negative 
women. The most notable difference between HIV-positive and HIV-negative women 
was the more than doubled rate of progression from HPV to HSIL. True transition 
probabilities likely lie between the incident and prevalent curves as a function of age and 
sexual activity. 
  27 
While analyses of potential effect modifiers should be interpreted with caution due to 
limited sample sizes, overall results suggest that HIV-positive women with baseline 
CD4+ counts <200 (cells/µL), infection with HPV-16/18, or concurrent infection with 
multiple HPV types had higher rates of progression and lower rates of regression. Data 
on ART were limited for several studies included in the analysis; therefore, the impact of 
baseline CD4+ count was examined to capture some of these treatment effects. Although 
some studies suggest that ART and improved CD4+ counts may reduce adverse 
transitions [151-153], the impact on cervical cancer incidence not been demonstrated 
[154]. Consistent with other research [97, 98], this study found increased incident 
detection of multiple HPV types in HIV-positive women compared to HIV-negative 
women, but also demonstrated that infection with multiple types increased progression 
and decreased regression. This is particularly important as >1 type was present in 71% of 
visits in which HIV-positive women had HPV detection, in comparison to 28% among 
HIV-negative women. 
Evidence regarding the role of HIV type on the natural history of HPV is conflicting 
[3, 122, 141, 155-159], with some research indicating that HIV-2 is more strongly 
associated with HPV-related disease than HIV-1. In contrast, the present analysis found 
HIV-1 to be more strongly associated with adverse transitions than HIV-2 (with the 
notable exception of a lower probability of transitioning from Normal to HSIL). HIV-1 
has a shorter incubation period, higher transmissibility, and more rapid development of 
immunosuppression compared to HIV-2 [66, 139]. Thus, it is biologically plausible that 
women with HIV-1 are at greater risk due to more severe immunosuppression. However, 
longer survival among women with HIV-2 [160] may result in higher lifetime risk due to 
extended time to develop cervical cancer. Dissimilar findings may be a function of 
methodological approaches with case-control and cross-sectional research detecting 
effects of differential survival, and longitudinal research involving short-term follow-up, 
such as the present analysis, detecting effects of differential immunosuppression. 
This study has several limitations. The present analysis focused on three stages of 
natural history: Normal (defined as HPV-negative), HPV (defined as HPV-positive with 
one or more type and the absence of HSIL), or HSIL (defined as HPV-positive with one 
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or more type and the presence of HSIL). Importantly, if a woman went from HPV-
positive with type 16 to HPV-positive with type 18 in consecutive visits this was 
classified as a continuation of the HPV stage. This situation was unusual as many women 
had multiple HPV types such that one type was persistent during consecutive HPV visits. 
With varying protocols across studies, clinic visits in which biopsies were not indicated, 
and limited participant follow-up, histology was only available for 10% of all clinic 
visits. In the absence of histology, cytology was used to inform classification of women 
into natural history stages. Misclassification resulting from cytology likely leads to 
undetected cervical abnormalities (e.g. false negatives), such that some women are 
classified as HPV when in fact they are HSIL. Thus, progression to HSIL may be 
underestimated while regression from HSIL may be overestimated. However, it is 
important to note that histology is an imperfect gold standard with demonstrated low 
reproducibility [146]. A number of screening and diagnostic technologies were utilized in 
these studies with validity improving over time, which may produce time-varying 
misclassification. However, the overall performance of HIV typing and PCR detection of 
HPV DNA have been demonstrated to be high throughout these studies, such that the 
likelihood of substantial time-varying misclassification is small. Estimates of natural 
regression from HSIL may be overestimated due to biopsy or treatment effects, yet 
participant follow-up for treatment was low in earlier studies, thus these effects are likely 
minimal. While most clinic visits occurred in four month intervals there were cases with 
longer lapses between visits, increasing the interval censoring and the possibility of 
missed transitions between visits. Further, this sample is largely comprised of women in 
their thirties who may have been previously infected with HPV, such that a positive HPV 
test represents incident DNA detection rather than incident infection (i.e. reactivation 
effects).  
This study has a number of strengths, most notably a large longitudinal sample to 
directly compare HIV-positive and HIV-negative women. These data allowed for the 
examination of the impact of HIV type, as both HIV-1 and HIV-2 are endemic to West 
Africa. HPV-16 and HPV-18 were tested for in each study included in the analysis; 
therefore, we were able to examine the roles of these highly oncogenic types separate 
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from other types. Further, this sample is diverse and includes both Muslim women in 
polygamous marriages as well as registered CSWs. As CSW are estimated to represent 
roughly 25% of new HIV cases in Africa, this population is particularly relevant for co-
infection research [161]. Finally, factors known to impact HPV natural history are 
minimal in this sample (e.g. oral contraception use, smoking, prior cervical cancer 
screening/treatment, and HPV vaccination). 
 
C6. Conclusion 
Findings suggest that targeted prevention programs for HIV-positive women are 
needed. However, cost-effectiveness analyses specific to the HIV-positive population in 
sub-Saharan Africa should be developed as the relative impact of screening and 
vaccination strategies may be different for this high-risk group than the general 
population. For instance, given the high prevalence of HPV among HIV-positive women, 
HPV testing as a stand-alone strategy may be inefficient for identifying women for 
targeted follow-up. The importance of identifying optimal targeted prevention strategies 
is further highlighted by modeling evidence suggesting that cervical cancer among HIV-
positive women may increase in the future due to extended life expectancy resulting from 
ART [154, 162].  
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D. MANUSCRIPT II: Identifying Optimal Cervical Cancer Screening Approaches 
for HIV-positive Women in Senegal, West Africa - A Markov Cohort Cost-
Effectiveness Model 
 
D1. Summary 
Background. Cervical cancer prevention strategies specific to the high-risk population 
of HIV-positive women in sub-Saharan Africa remain limited due, in part, to uncertainty 
regarding optimal approaches. This paper examines the cost-effectiveness of screening 
strategies relevant to Senegal, West Africa. 
Methods. Using Markov cohort modeling with a 4-month cycle over a 15-year time 
horizon, we examined the relative cost-effectiveness of six screening strategies (Hybrid 
Capture 2 HPV testing, rapid HPV testing, cytology, visual inspection with acetic acid 
(VIA), HPV testing followed by cytology triage, and HPV testing followed by VIA 
triage) and five screening frequencies using projected life expectancy and incremental 
cost-effectiveness ratios (ICER). One-way and probabilistic sensitivity analyses were 
conducted to explore the impact of uncertainty on results. 
Results. In base case analyses, VIA was the most cost-effective strategy examined. 
Compared to no screening, annual VIA resulted in a discounted increased life expectancy 
of 1.7 months and a 40% reduction in cervical cancer incidence with an ICER of I$1,500 
per life year saved. When accounting for uncertainty, VIA and cytology emerge as the 
most likely to be cost-effective. High underlying HPV prevalence among HIV-positive 
women significantly reduces the cost-effectiveness of HPV testing. 
Conclusions. Cost-effective strategies for targeted cervical cancer screening among 
HIV-positive women represent an important prevention opportunity among this high-risk 
population.  
 
D2. Background 
Human papillomavirus (HPV) is the necessary cause of squamous cervical cancer 
[132], is highly transmissible, and generally acquired closely after sexual debut [133, 
134]. Persistent infection can lead to the development of pre-cancerous lesions which, in 
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the absence of treatment or an immune response, can progress to cancer. High-risk HPV 
types 16 and 18 are estimated to account for 70% of cervical cancer [11]. Women with 
human immunodeficiency virus (HIV) infection are at an increased risk for detection of 
HPV, pre-cancerous cervical lesions, and cervical cancer compared to HIV-negative 
women [3, 90-92, 96, 99, 103, 122, 135]. Cervical cancer is the leading cause of cancer 
mortality among women in sub-Saharan Africa (SSA) [58] where 70% of the global HIV 
burden is concentrated [65]. 
Cervical cancer is entirely preventable yet disproportionately impacts developing 
regions with limited access to prevention services. Several studies and pilot projects have 
demonstrated the feasibility of implementing cervical cancer screening and treatment in 
low-resource settings [163], although significant economic and infrastructural challenges 
remain [164]. While screening with cytology has been widely adopted in developed 
nations resulting in major declines in cervical cancer incidence over the past 60 years, 
significant laboratory, equipment, and clinical expertise requirements have limited the 
capacity to establish cytology in low-resource settings [164, 165]. Further, cytology has 
low reproducibility and sensitivity in comparison to other strategies, necessitating 
frequent screening to achieve high effectiveness [146, 165]. As such, a substantial effort 
has been made to identify and evaluate screening strategies that are more contextually 
relevant for the high-risk setting of SSA. Hybrid Capture 2 (HC2) HPV testing is highly 
sensitive and reproducible with the potential for self-collection of samples [166], yet 
requires significant investment in laboratory equipment and technician expertise [164]. 
Both cytology and HPV testing involve laboratory processing time leading to delays in 
obtaining results and an additional clinic visit if treatment is needed. Visual inspection 
with acetic acid (VIA) may be most suitable to low-resource settings as it involves naked 
eye inspection of the cervix (yielding immediate results), and requires little clinical 
expertise and no laboratory equipment for processing samples. However, inter-observer 
differences in subjectively determining positivity, concerns regarding over treatment, and 
the potential for small lesions to remain undetected may reduce the effectiveness of VIA 
[164]. The more recently developed careHPVTM test offers the benefits of standard HPV 
testing, but yields rapid results (roughly two hours of processing time), mobile battery 
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operated processing equipment, and minimal technical training [164, 167]. Both VIA and 
rapid HPV testing can be implemented as part of a same day ‘screen and treat’ approach, 
minimizing losses to follow-up and delayed treatment. Immediate treatment with 
cryotherapy has minimal infrastructure requirements and can be provided by nurses and 
midwives [164]. In contrast, surgical treatment with conization or loop electrosurgical 
excision procedure (LEEP) require significant infrastructure and technical training, and 
are further limited by the lack of pathology services in SSA settings [168].  
Importantly, the performance of test and treatment modalities can be reduced when 
applied to HIV-positive women adding further uncertainty regarding optimal cervical 
cancer prevention strategies for this high-risk population. The United States (US) 
President’s Emergency Plan for AIDS Relief (PEPFAR) has provided support for limited 
efforts to initiate cervical cancer screening programs for HIV-positive women in some 
countries, such as Ethiopia, Tanzania, and Zambia [169]. PEPFAR-supported 
interventions include VIA screening and treatment with cryotherapy or LEEP, although 
the impact of these modalities on morbidity and mortality among this population has not 
been clearly demonstrated. 
In summary, despite demonstrated successes in both research and pilot projects 
working to overcome challenges and identify contextually relevant approaches, no SSA 
country has currently successfully implemented a national population-based cervical 
cancer screening program. Thus, there is a pressing need for a targeted approach to best 
allocate resources to high-risk populations, such as HIV-positive women, and inform the 
eventual implementation of comprehensive population-based screening paradigms [170]. 
As there are no published cost-effectiveness analyses for cervical cancer screening 
specific to HIV-positive women in Africa, there is uncertainty regarding the most optimal 
and contextually relevant approach. Given the distinct natural history of HPV among 
HIV-positive women, as well as varying test and treatment attributes, it is important to 
quantitatively compare the potential impact of screening strategies to understand how 
these factors collectively impact HPV-associated morbidity and mortality. To address this 
gap in the literature, we constructed a simulation model to examine the relative cost-
effectiveness of cytology, VIA, HC2 HPV testing, rapid HPV testing, rapid HPV DNA 
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testing followed by cytology triage, and rapid HPV DNA testing followed by VIA triage 
among HIV-positive women in Senegal, West Africa. 
 
D3. Materials and Methods  
A Markov cohort model was developed to simulate the natural history of HPV and 
the development of cervical cancer among HIV-positive women, with screening and 
treatment scenarios overlaid to determine the relative cost, life expectancy, and cost-
effectiveness of each strategy. A 4-month cycle was used as the natural history of HPV is 
transient such that a short interval is needed to capture clinically relevant transitions (in 
other words the model simulates time in 4-month iterations). A 15-year time horizon was 
used, with women entering the model at time of HIV diagnosis (to simulate a point-of-
care approach for initiation of screening while leveraging existing HIV care 
infrastructure). Five screening frequencies were examined (baseline only, baseline and 
five year screening, baseline with five and ten year screenings, triennial, and annual) 
resulting in one, two, three, six, and fifteen total screens. 
D3.1 Input data (Table 6) 
Using data described previously [171], competing risk modeling was used to estimate 
natural history transition probabilities. Briefly, 575 HIV-positive women were followed 
for an average of two years in Senegal between 1994 and 2010. Cytology (with histology 
in a sub-sample of women) and HPV DNA testing were performed at approximately 4-
month intervals. At each visit, women were classified into one of five mutually exclusive 
natural history states: Normal (defined as HPV-negative), HPV-16/18 (defined as HPV-
positive with at least type 16 and/or 18), HPV-Other (defined as HPV-positive with the 
absence of types 16/18), CIN2/3-16/18 (defined as HPV-16/18 with the presence of 
CIN2/3), and CIN2/3-Other (defined as HPV-Other with the presence of CIN2/3). These 
five health states, combined with invasive cervical cancer (ICC) and death, comprise the 
underlying natural history model (Figure 6). Baseline screening data from Senegal were 
used to populate states at the beginning of the model (i.e. initial vector parameterization). 
Death from other causes among HIV-positive women was estimated from the literature 
with a wide-range of heterogeneity in the underlying study samples to conservatively 
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account for uncertainty in this parameter given the role of competing risks, as well as 
access and adherence to anti-retroviral treatment (ART) [81, 172-174].  
Estimates for screening test performance were derived from the literature specific to 
HIV-positive women using histology as the gold standard, with multiple sources forming 
a range and the midpoint used as a base estimate. Estimates specific to rapid HPV testing 
among HIV-positive women were limited; thus, the relative performance of rapid testing 
compared to HC2 among HIV-negative women was used to calculate estimates of 
validity for the present analysis. 
Given established feasibility for implementation in low-resource settings [175, 176], 
cryotherapy was the primary treatment for pre-cancerous lesions. Cases in which women 
were ineligible for cryotherapy given the size of the lesion were assumed to be referred 
for LEEP, with the proportion requiring LEEP estimated from literature specific to HIV-
positive women in SSA [177-179]. Due to lack of chemotherapy and radiation 
availability within Senegal and the broader area of SSA, we assumed hysterectomy-only 
treatment for cancer. A proportion of women with late stage cervical cancer were 
assumed to present with symptoms (independent of available screening initiatives), 
consistent with other models. Estimates of treatment effectiveness were established from 
the literature specific to HIV-positive women, with multiple sources informing a base and 
range for sensitivity analyses. Studies in which pre-cancer recurrence was established 
after approximately one year of follow-up were given greater weight for estimation of 
treatment effectiveness, as longer follow-up may lead to detection of disease resulting 
from new infections as opposed to recurrence (leading to an underestimate of 
effectiveness). As the underlying natural history model accounts for newly acquired and 
reactivated infections at the aggregate level, inclusion of estimates of effectiveness from 
studies with extensive follow-up could lead to double counting of recurrence. All follow-
up treatment was simulated to occur within the same 4-month cycle as screening. 
For the base analysis, participation in follow-up testing and treatment was assumed to 
be 100%. Sensitivity analyses exploring the impact of less than perfect retention for 
strategies involving multiple visits (ex: referral for LEEP or cytology followed by 
treatment) were conducted, with retention estimates based on literature specific to HIV-
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positive women in SSA. For strategies employing a same day ‘screen and treat’ approach 
retention rates were held at 100% to capture the benefits of averted losses to follow-up.  
In the absence of costs for screening and treatment specific to Senegal, estimates were 
established from literature specific to low-resource nations in SSA, with multiple sources 
forming a range and the midpoint used as a base estimate. All sources included direct 
medical costs including staff, supplies, equipment, and specimen transport. Additionally, 
some sources also incorporated estimates of women’s traveling and time costs (notably, 
these additional costs represented a small fraction of estimates for a given 
test/procedure). Costs specific to rapid HPV testing in SSA were unavailable; thus, the 
relative cost of rapid testing compared to VIA in other low resource nations was used to 
calculate estimated costs for the present analysis. Costs in the literature were expressed in 
either US or international dollars (I$). I$ are a hypothetical currency in which national 
currencies are transformed into a common currency, the US dollar, based on price 
differences between countries. I$s have the same purchasing power as US dollars in the 
US. To standardize estimates and account for inflation, costs were updated to 2013 
international dollars using Senegalese purchasing power parity (PPP) exchange rates and 
consumer price index (CPI) deflators. 
D3.2 Calibration –  
In the absence of estimates of cervical cancer risk specific to HIV-positive 
populations, the natural history model was calibrated to 2012 GLOBOCON estimates for 
Senegal [61] with a multiplier ranging from two to eight to capture the relative effect of 
HIV as reported in the literature [3, 88, 103-106, 180, 181]. The Nelder-Mead direct-
search algorithm [182, 183] with 10,000 initial value combinations was employed to 
minimize sums of squares between simulation outcomes and calibration targets. Natural 
history estimates which best optimized model fit and were biologically relevant were 
selected (e.g. risk of progression to cancer was greater for HPV-16/18 than other types, 
with HPV-16/18 accounting for approximately 70% of cervical cancer) [11, 130]. Inputs 
for the base analysis were calibrated for a five-fold increase in cervical cancer risk with 
the top ten percent of best fitting estimates for two- to eight-fold increases forming the 
lower and upper bounds, respectively, for sensitivity analyses. To assess internal validity 
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of the natural history model, outputs were compared to reported HPV and CIN2/3 
prevalence from studies used to estimate natural history transitions with high agreement 
observed [3]. Model outputs were also compared to literature from the broader area of 
SSA to assess external validity. Specifically, prevalence of HPV [92, 93], HR-16/18 
[184], and high-grade lesions [185], as well as HPV-16/18 positivity among women with 
high-grade lesions [96], were compared with high agreement observed between study 
results and model output. Lastly, the model was reviewed by Senegalese clinicians 
providing care to HIV-positive women to ensure face-validity of key inputs, outputs, and 
assumptions. Calibration was conducted using R Studio 3.1 (Boston, MA, USA). 
D3.3 Analysis 
The relative performance of each screening strategy was measured using incremental 
cost-effectiveness ratios (ICERs) which represent the cost of an additional unit of 
effectiveness that is obtained when implementing a more effective strategy rather than a 
less effective strategy. Strategies that were more costly and less effective than another 
(i.e. strongly dominated) and strategies with a higher ICER than a more effective 
alternate strategy (i.e. weakly dominated) were eliminated. Based on World Health 
Organization recommendations, strategies with ICERs less than Senegal’s 2013 per 
capita Gross Domestic Product (GDP) were considered ‘very cost-effective’ 
(approximately I$1,050) and strategies less than three times the per capita GDP were 
considered ‘cost-effective’ (approximately I$3,150) [5, 186]. One-way sensitivity 
analyses were conducted to assess the influence of uncertainty in key parameters on 
results. To simultaneously account for uncertainty in all input parameters, a probabilistic 
sensitivity analysis with 50,000 samples from uniform distributions was conducted with 
results displayed in a cost-effectiveness acceptability curve (CEAC) representing the 
Bayesian probability that a given screening strategy will be cost-effective across varying 
levels of willingness-to-pay thresholds. Future costs and life years were discounted at an 
annual rate of 3%. Markov cohort cost-effectiveness modeling was conducted in TreeAge 
Pro 2015 (Williamstown, MA, USA). IRB approval was not necessary for this study as 
the existing data do not meet the criterion for human subjects’ research. 
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D4. Results 
D4.1 Base-case analysis (Table 7)  
With no screening, discounted fifteen year costs per woman and life expectancy were 
I$66 and 9.55 years, respectively (costs accrued under a no screening paradigm are the 
result of women seeking medical care given presentation of cervical cancer symptoms). 
VIA was ‘very cost-effective’ for all screening frequencies examined, except for annual 
screening. Specifically, annual VIA resulted in a discounted increased life expectancy of 
1.7 months with an ICER of I$1,500 per life year saved (remaining below the threshold 
for ‘cost-effective’). Cervical cancer incidence and mortality were reduced by 40% and 
70%, respectively, with annual VIA when compared to no screening. Cytology, rapid 
HPV testing, and rapid HPV testing followed by either VIA or cytology triage remained 
dominated for all screening frequencies examined. HC2 was not dominated; however, the 
ICERs far exceeded the willingness-to-pay threshold. 
VIA and cytology consistently resulted in fewer false-positives than other strategies. 
While rapid HPV testing followed by VIA or cytology triage resulted in the highest 
number of false-positives test results, the second round of screening following a positive 
HPV test lead to a substantial reductions in unnecessary referrals to treatment 
(approximately a 65% reduction compared to VIA). Notably, HC2 and rapid HPV as 
stand-alone testing strategies resulted in the highest number of unnecessary treatment 
referrals (approximately 20% greater than VIA), likely a function of high underlying 
HPV prevalence among HIV-positive women. 
D4.2 Sensitivity analyses (Table 8)  
One-way sensitivity analyses with three screenings (i.e. baseline, five and ten year 
testing) revealed that estimates of incremental cost-effectiveness were most influenced by 
retention in care, progression to cervical cancer, cervical cancer mortality in the absence 
of treatment, and the potential impact of ART. Results were less sensitive to discounting, 
death from other causes, and pre-cancer treatment effectiveness, with no meaningful 
impact on relative cost-effectiveness. Of note, the limited impact of discounting on 
results is partially a function of the 15 year time horizon used for present analysis (i.e. 
discounting becomes more influential as the time horizon is extended (data not shown)). 
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Potential losses to follow-up were considered for strategies involving follow-up visits 
(e.g. cytology) and treatment referrals requiring LEEP as opposed to same-day treatment 
with cryotherapy. Overall, as retention is reduced, both the costs and effects for each 
strategy decrease as well. Specifically, as retention in care fell below 70% the cost of 
VIA exceeded that of cytology (as fewer women successfully follow-up with treatment 
after a positive cytology result, reducing total costs); however, costs decline at a faster 
rate than effects such that cytology becomes more competitive on a relative scale. For 
instance, with 50% retention in care, three VIA screens resulted in an ICER of I$1100 per 
life year saved in comparison to I$640 for cytology. Notably, the impact of less than 
perfect retention in care on effectiveness is attenuated as screening frequency increases 
with the opportunity to address any missed follow-up during a future visit.  
Strategies became more cost-effective with accelerated progression to cervical cancer. 
Specifically, under a maximum progression scenario, three VIA screens resulted in an 
ICER of I$414 per life year saved. In contrast, with minimum progression the ICER for 
annual VIA was I$475 per life year saved (remaining below the threshold for ‘cost-
effective’). 
With increasing cervical cancer mortality given the absence of treatment, screening 
becomes more cost-effective (as the impact of screening on cervical cancer death 
increases and the ICER becomes smaller). Under a maximum cervical cancer mortality 
scenario, the ICER for three VIA screenings is I$653, in comparison to I$1,056 under a 
minimum cervical cancer morality scenario. 
Given evidence that higher CD4+ counts are associated with improved clearance of 
infection, regression from pre-cancers lesions, and treatment effectiveness [151-153, 171, 
187, 188], we examined the potential impact of ART access and adherence. Specifically, 
maximum progression and death inputs with minimum regression inputs were used to 
simulate the potential effects of low ART coverage, while minimum progression and 
death inputs with maximum regression inputs were used to simulate high ART coverage. 
The ICERs for three VIA screens under low and high ART coverage scenarios were 
I$237 and I$2,298, respectively. Similar to the impact of cervical cancer mortality, the 
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impact of screening increases under a maximum progression scenario, resulting in 
smaller ICERs. 
When accounting for uncertainty in all inputs simultaneously (i.e. initial vector 
parameterization, natural history transitions, death from other causes, death from cervical 
cancer, treatment effectiveness, screening performance, and costs), VIA and cytology 
were probabilistically the most likely cost-effective screening strategies (Figure 7). 
Cytology emerged as a cost-effective strategy in 16-28% of iterations when examining 
results beyond a willingness-to-pay threshold of I$600. Base estimates for test 
performance were similar for VIA and cytology; however, the upper ranges for cytology 
sensitivity and specificity slightly exceed that of VIA. Similarly, plausible ranges for cost 
of VIA and cytology overlap. In those cases in which cytology was more cost-effective 
than VIA, inputs from upper bounds of test performance and lower bounds for cost were 
selected. Collectively these two factors drive the emergence of cytology as a potentially 
cost-effective strategy.  
 
D5. Discussion 
The objective of this model was to provide insight into the potential impact of 
existing cervical cancer screening tools in the high-risk population of HIV-positive 
women in Senegal. As HIV-positive women are at an increased risk of cervical cancer it 
is critical to explore potential prevention strategies while collectively accounting for the 
distinct natural history, screening performance, treatment effectiveness, and competing 
risks factors within this population. Markov cohort modeling provides an important tool 
for quantitatively and simultaneous accounting for these factors. When accounting for a 
wide range of all input parameters, this simulation model found that VIA and cytology 
are ‘very cost-effective’ with ICERs below I$1,050 per life year saved. Results were 
largely driven by relative differences in costs as effects on life expectancy were similar 
across the screening strategies examined. Notably, the impact of screening, as measured 
by life expectancy, is averaged across the simulated cohort such that the discounted 
increased life expectancy of 1.7 resulting from annual VIA yields approximately 2,830 
additional life years among the estimated 20,000 HIV-positive women in the Senegal.  
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Importantly, VIA may be more contextually suitable for lower-resource settings given 
minimal infrastructural and technical expertise requirements. Mexico’s national cytology 
program was largely ineffective over several decades despite the fact that they had 
considerably greater resources and existing medical infrastructure than Senegal and much 
of SSA [189-191]. Limited quality control, lack of equipment maintenance, and poor 
reporting of results to patients were identified as significant contributors to sub-optimal 
outcomes. Successful implementation of a cytology screening program requires 
significant and sustained quality control measures, including regular independent re-
reading of samples, staff trainings, and laboratory inspections. Further, a key assumption 
of cost-effectiveness analyses is that given the funding, all necessary components of an 
intervention can be purchased. While tangible items required for the screening strategies 
examined can be purchased and shipped to areas within SSA, this assumption is unlikely 
to be met in terms of the labor force required for cytology, specifically trained and 
qualified cytotechnologists. VIA can be implemented with limited technical expertise by 
a wide range of medical providers (including nurses and midwives); however, the 
processing of cytology results requires specialized laboratory technicians, a labor force 
which would have to be developed with additional funds in advance. These factors should 
be considered when interpreting the emergence of cytology as a cost-effective strategy in 
probabilistic sensitivity analyses and during policy decision-making. 
HPV testing strategies remained consistently dominated (i.e. more costly and less 
effective than alternate strategies) or far exceeded the willingness-to-pay threshold. This 
is likely a function of the lower specificity of HPV testing in comparison to cytology and 
VIA, and high underlying HPV prevalence among HIV-positive women. For instance, 
one study from which data were used to inform estimates of natural history found that 
roughly 67% of HIV-positive women had prevalent HPV detection in comparison to 25% 
of HIV-negative women [3]. Essentially, given high HPV positivity among HIV-positive 
women, HPV DNA testing results in the majority of women referred for costly follow-up 
testing and/or treatment, such that the test functionally does little in terms of focusing 
resources on those who are at greatest risk. Recalibrating HPV testing positivity cut-
points specifically for an HIV-positive population may improve overall test performance 
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and should be investigated [192]. However, improved specificity results in diminished 
sensitivity, the effects of which should be simulated to determine optimal trade-offs. 
Further, genetic markers of proliferative lesions, including p16 and mRNA coding for the 
viral E6 and/or E7 proteins, could be used in combination with HPV testing to improve 
test performance [193]. The resulting costs and application to HIV-positive populations 
have not been established in the literature, but warrant consideration. 
This analysis has several limitations. Estimates of cervical cancer risk may be 
misestimated due to both the unknown relative increase in risk among HIV-positive 
women and uncertainty regarding incidence in the general population. GLOBOCAN 
predictions incorporate methods to overcome the likely underreporting of cervical cancer 
by using a combination of cancer registry, autopsy, and published research data, 
algorithms to weight data quality, and extrapolation of data from geographically linked 
areas; however, uncertainty remains [58]. To address this limitation, a wide range of 
multipliers were used, with sensitivity analyses demonstrating that results remained 
robust across a number of cancer risk scenarios. Much of the literature on screening 
performance among HIV-positive women was specific to low-resource settings, which 
both increases the face-validity of the model to the current context of screening in SSA 
but also yields lower estimates of validity than that obtained in developed settings. 
Further, estimates of costs are subject to probable extensive situational heterogeneity as 
they are largely dependent on transportation, labor, and scaling factors [169, 194]. 
Therefore, literature specific to any low-resource SSA countries was included yielding a 
wide range for cost estimates to conservatively represent uncertainty in these parameters. 
Possible increases in HIV transmission due to inflammation and bleeding following 
cryotherapy and LEEP were not examined. To date, no study has examined potential 
transmission implications resulting from treatment [195]; however, as one study reported 
that half of HIV-positive women had sex during the month after treatment against 
medical recommendation [135], the potential for increased HIV transmission is not trivial 
and highlights the need for comprehensive education and risk communication specific to 
HIV-positive women and their partners. Finally, the present model is ageless in that 
screening initiation is assumed to occur at the time of HIV diagnosis with mortality and 
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natural history estimates averaged across age. This approach was taken for several 
reasons. First, evidence suggests that in contrast to observed patterns in HIV-negative 
women, age is not strongly associated with the natural history of HPV among HIV-
positive women, likely due to increased persistence and infection with multiple types 
[118, 131, 171]. Second, there is likely significant heterogeneity in age at the time of HIV 
diagnosis. For instance, testing strategies often target high-risk populations (such as 
commercial sex workers) which may overlook key sub-populations (such as married 
women in polygamous relationships) resulting in heterogeneity in age at time of HIV 
diagnosis. The average age of the underlying cohort used to estimate natural history 
transitions was 34 years. Importantly, among those diagnosed in their teens or early 
twenties potentially delaying initial screening until their 30’s should be considered to 
optimized resources and outcomes, especially in circumstances when a one lifetime 
screening approach is adopted. 
The internal validity of this model is likely enhanced as natural history estimates were 
derived from a single Senegalese study population with a large sample of HIV-positive 
women using methods that specifically yield transition probabilities. However, the 
broader exchangeability of these parameters should be considered when generalizing 
findings. For instance, transitions from Normal to HPV are a function of both biological 
and behavioral factors (i.e. the biological risk of transmission given exposure and the 
more behaviorally driven risk of exposure given sexual behavior which may vary 
geographically). Further, of the Senegalese sample used to estimate natural history 
parameters, the median CD4+ count at baseline was 416 cells/µL with 27% of women 
reporting use of ART [171]. There is evidence that higher CD4+ counts are associated 
with improved clearance of infection, regression from pre-cancers lesions, and treatment 
effectiveness [151-153, 171, 187, 188]. However, at the population level any protective 
effects of ART and improved CD4+ counts on cervical cancer incidence have yet to be 
clearly demonstrated [154]. Additionally, there is evidence that cervical cancer among 
HIV-positive women may increase in the future due to extended life expectancy resulting 
from ART (providing greater time to acquire HPV and develop cancer) [154, 162]. 
Sensitivity analyses exploring the potential impact of ART coverage were conducted 
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demonstrating that VIA remained a ‘cost-effective’ strategy across a wide range of 
natural history inputs. Importantly, given the demonstrated stability of findings in one-
way and probabilistic sensitivity analyses, there may be a reasonable foundation upon 
which to generalize findings to SSA nations with similar economic and social 
characteristics. Additional research examining relative cost-effectiveness among key sub-
populations (e.g. urban and rural areas, commercial sex workers) should be conducted. 
  
D6. Conclusion 
Cervical cancer remains a key public health challenge despite major advancements in 
screening and treatment options. Several research and demonstration projects have 
established the feasibility of cervical cancer screening in low-resource settings, yet 
infrastructural, training, and financial demands have prevented wide-scale 
implementation of population-based screening programs in much of the high-risk setting 
of SSA. This research is the first comprehensive comparison of multiple screening 
strategies among this high-risk population. Results demonstrate that cervical cancer 
screening among HIV-positive women is cost-effective, such that they are an ideal 
population for targeted screening to both reduce preventable disease and prioritize limited 
resources. 
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E. MANUSCRIPT III: Potential Cost-Effectiveness of Targeted HPV Vaccination in 
HIV-positive Women in Senegal, West Africa: A Theoretical Exploratory Analysis 
 
E1. Summary 
Background. Cervical cancer prevention strategies specific to the high-risk population 
of HIV-positive women in sub-Saharan Africa remain limited due to, in part, uncertainty 
regarding optimal approaches. This paper examines the potential cost-effectiveness of 
targeted HPV vaccination among adult HIV-positive women in Senegal, West Africa. 
Methods. Using Markov cohort modeling with a 4-month cycle over a 15-year time 
horizon, we examined the relative cost-effectiveness of vaccination for several scenarios 
based on various estimates of potential vaccine effectiveness and cost using projected life 
expectancy and incremental cost-effectiveness ratios (ICER). Specifically, vaccination at 
the time of HIV diagnosis was examined under various theoretical effectiveness 
scenarios, with comparison to visual inspection with acetic acid (VIA) screening (at 
baseline, year five, and year ten). One-way sensitivity analyses were conducted to 
explore the impact of uncertainty on results. 
Results. HPV vaccination was only cost-effective under optimal vaccine efficacy 
and/or costing scenarios. Specifically, with costs ≥I$31 vaccination became dominated 
when vaccine efficacy fell below approximately 70% and 40% for reducing transitions 
from Normal to HPV-16/18 and HPV-Other states, respectively.  
Conclusions. With lower vaccine-induced titer levels reported among adult HIV-
positive women and a potential corresponding reduction in vaccine efficacy, HPV 
vaccination costs must be reduced for primary prevention to be cost-effective in 
comparison to screening. Efforts to implement targeted screening, reduce vaccine costs, 
develop therapeutic vaccines, and evaluate upcoming HPV antiviral treatments should be 
made for this high-risk population. 
 
E2. Background 
Human papillomavirus (HPV) is the necessary cause of squamous cervical cancer 
[132], is highly transmissible, and generally acquired closely after sexual debut [133, 
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134]. Approximately 40 genotypes infect the genital tract with types classified 
hierarchically based on their oncogenic potential. Persistent infection can lead to the 
development of pre-cancerous lesions which, in the absence of treatment or an immune 
response, can progress to cancer. Women with human immunodeficiency virus (HIV) 
infection are at an significantly increased risk for detection of HPV, pre-cancerous 
cervical lesions, and cervical cancer compared to HIV-negative women [3, 90-92, 96, 99, 
103, 122, 135]. Cervical cancer is the leading cause of cancer mortality among women in 
sub-Saharan Africa (SSA) [58], an area with only 5% of global cancer resources and 70% 
of the global HIV burden [65].  
There are currently three prophylactic HPV vaccines available: a bivalent vaccine 
which protects against types 16 and 18 (Cervarix, GSK), a quadrivalent vaccine which 
protects against types 6, 11, 16, and 18 (Gardasil, Merck & Co.), and the recently 
approved nonavalent which protect against types 6, 11, 16, 18, 31, 33, 45, 52, and 58 
(Gardasil 9, Merck & Co.). The bivalent and quadrivalent vaccines protect against those 
types that collectively cause 70% of cervical cancer (HPV types 16 and 18), while the 
nonavalent affords extended protection against types collectively attributable to 90% of 
cervical cancer [9, 11, 40]. Additionally, the quadrivalent and nonavalent vaccines 
protect against HPV types 6 and 11 which cause over 90% of anogential warts [10]. All 
three HPV vaccines have been shown to be safe and elicit strong immune responses with 
subsequent demonstrated reductions in cervical HPV infection and cervical intraepithelial 
neoplasia (CIN) pre-cancerous lesions [43-45, 196, 197]. The duration of protection 
remains unknown, although participants from early phase III clinical trials are being 
actively followed with no evidence of waning immunity 8.5  years post-vaccination [51]. 
Notably, the bivalent and quadrivalent vaccines elicit cross-protection to other HPV types 
that are phylogenetically related to those included in the vaccine [47, 198]. However, 
early evidence indicates that the nonavalent vaccine does not induce protective effects for 
non-vaccine HPV types [43]. 
While many developed nations now recommend routine HPV vaccination for 
adolescent boys and girls prior to sexual debut, implementation of vaccination in low-
resource settings presents significant financial and infrastructural challenges. The HPV 
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vaccine is a three-dose series and is the most expensive publically funded vaccine at 
roughly $300 in the United States. Thus, it is cost-prohibitive for many countries to 
implement mass vaccination campaigns although recent efforts to subsidize HPV 
vaccination costs by GAVI hold promise in terms of expanding access in low-resource 
high-risk settings. However, the GAVI subsidized series costs $15, which far exceeds the 
average cost of vaccines included in WHO-UNICEF Global Immunization program 
[199]. While GAVI covers the full cost of HPV vaccines for initial demonstration 
programs that are required as part of a successful application for GAVI support, countries 
that implement national HPV vaccination programs must meet a co-financing 
requirement. Further, GAVI support is only available to the “poorest countries” with a 
Gross National Income (GNI) per capita less than $1,580. Forty-nine countries meet this 
criterion, of which 20 have been approved for demonstration projects to assess their 
capacity to successfully administer a vaccine to adolescent girls. Senegal is eligible for 
GAVI assistance and is currently implementing a demonstration program as part of the 
application process. In addition to financial obstacles, the infrastructure of existing 
vaccination programming is largely designed for point-of-care administration to infants 
and mothers, and young school-aged children as a population of convenience. As such, 
infrastructure specific to vaccinating adolescent girls in low-resource settings is limited. 
Due to these challenges there is growing interest in identifying possible populations for 
targeted vaccination efforts to both reduce cost and maximize benefits. 
HIV-positive women may be a key population for targeted vaccination as they are at 
an increased risk of cervical cancer and vaccination has the potential to be incorporated 
into existing HIV care services. The safety and immunogenicity of the HPV vaccine in 
HIV-positive populations has been demonstrated in several clinical trials with 
seroconversion rates ≥90% [53, 200-204]. However, some studies have found lower 
vaccine-induced antibody titer levels in HIV-positive participates compared to  HIV-
negative controls [53, 201, 204]. The effect of reduced titer levels in HIV-positive 
women remains unknown as there is no known correlate for immunity (i.e. the lowest 
level of immune response required to sufficiently confer immune protection remains 
unknown) [205]. HPV vaccine efficacy for clinical outcomes (i.e. incident HPV infection 
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and clinical disease) has not been established in HIV-positive populations, although 
several clinical trials are currently underway [55]. Despite the lack of demonstrated 
efficacy, both Australia and the United States currently recommend HPV vaccination for 
HIV-positive women. Importantly, GAVI funding for HPV vaccination is specific to 
adolescent girls, such that vaccine costs for HIV-positive adult women will likely exceed 
that of the subsidized series. Across a wide range of theoretical levels for vaccine 
efficacy and cost, we examined the potential impact of targeted HPV vaccination among 
adult HIV-positive women in Senegal, West Africa. Specifically, we used Markov cohort 
simulation model to estimate the relative cost-effectiveness of vaccination in comparison 
to screening with visual inspection to inform public health practice and resource 
allocation in resource limited settings. 
 
E3. Materials and Methods 
A Markov cohort model was developed to simulate the natural history of HPV and 
the development of cervical cancer among HIV-positive women, with vaccination 
overlaid to determine relative cost, life expectancy, and cost-effectiveness. A 4-month 
cycle was used as the natural history of HPV is transient such that a short interval is 
needed to capture clinically relevant transitions. A 15-year time horizon was used, with 
women entering the model at time of HIV diagnosis (to simulate a point-of-diagnosis 
approach for vaccination). Additionally, in prior analyses using this model [206], six 
cervical cancer screening strategies were evaluated with visual inspection with acetic acid 
(VIA) identified as the most cost-effective. This analysis includes VIA screening (at 
baseline, year 5, and year 10) for comparative purposes. 
E3.1 Input data (Table 9)  
Using data described previously [171], competing risk modeling was used to estimate 
natural history transition probabilities. Briefly, 575 HIV-positive women were followed 
for an average of two years in Senegal between 1994 and 2010. Cytology (with histology 
in a sub-sample of women) and HPV DNA testing were performed at approximately 4-
month intervals. At each visit, women were classified into one of five mutually exclusive 
natural history states: Normal (defined as HPV-negative), HPV-16/18 (defined as HPV-
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positive with at least type 16 and/or 18), HPV-Other (defined as HPV-positive with the 
absence of types 16/18), CIN2/3-16/18 (defined as HPV-16/18 with the presence of 
CIN2/3), and CIN2/3-Other (defined as HPV-Other with the presence of CIN2/3). These 
five health states, combined with invasive cervical cancer (ICC) and death, comprise the 
underlying natural history model (Figure 8). Baseline screening data from Senegal were 
also used to populate states at the beginning of the model (i.e. initial vector 
parameterization). Death from other causes among HIV-positive women was estimated 
from the literature with a wide-range of heterogeneity in the underlying study samples to 
conservatively account for uncertainty in this parameter given the role of competing 
risks, as well as access and adherence to anti-retroviral treatment (ART).  
Estimates for VIA screening performance were derived from the literature specific to 
HIV-positive women using histology as the gold standard, with multiple sources forming 
a range and the midpoint used as a base estimate. Given established feasibility for 
implementation in low-resource settings [175, 176], cryotherapy was assumed to be the 
primary treatment for pre-cancerous lesions. Cases in which women were ineligible for 
cryotherapy given the size of the lesion were assumed to be referred for LEEP, with the 
proportion requiring LEEP estimated from literature specific to HIV-positive women in 
SSA [177-179]. Due to lack of chemotherapy and radiation availability within Senegal 
and the broader area of SSA, we assumed hysterectomy-only treatment for cancer. A 
proportion of women with late stage cervical cancer were assumed to present with 
symptoms (independent of available screening initiatives). Estimates of pre-cancer 
treatment effectiveness were established from the literature specific to HIV-positive 
women, with multiple sources informing base and range for sensitivity analyses. Studies 
in which recurrence was established within one year of follow-up were given greater 
weight for estimation of treatment effectiveness, as longer follow-up may lead to 
detection of disease resulting from new infections as opposed to recurrence (leading to an 
underestimate of effectiveness). As the underlying natural history model accounts for 
newly acquired and reactivated infections at the aggregate level, inclusion of estimates of 
effectiveness from studies with extensive follow-up could also lead to double counting of 
recurrence. All follow-up treatment was assumed to occur within the same 4-month cycle 
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as screening. As VIA can be implemented as a same day ‘screen and treat’ approach, 
retention in follow-up care was assumed to be 100%. 
In the absence of data specific to Senegal we used previously published estimates of 
screening and treatment costs for low-resource nations in SSA, with multiple sources 
forming a range and the midpoint used as a base estimate. All sources included direct 
medical costs including staff, supplies, equipment, and specimen transport. Additionally, 
some sources also incorporated estimates of women’s traveling and time costs (notably, 
these additional costs represented a small fraction of estimates for a given 
test/procedure). Estimates of vaccination costs are based on literature reporting plausible 
theoretical ranges as the majority of low-resource African countries do not offer HPV 
vaccination or have existing infrastructure specific to vaccinating older adolescent girls, 
and the price is dependent on negotiations, scaling, and the role of international aid 
programs. Costs in the literature were expressed in either US or international dollars (I$). 
I$ are a hypothetical currency in which national currencies are transformed into a 
common currency, the US dollar, based on price differences between countries. I$s have 
the same purchasing power as US dollars in the US. To standardize estimates and account 
for inflation, costs were updated to 2013 international dollars using Senegalese 
purchasing power parity (PPP) exchange rates and consumer price index (CPI) deflators. 
As vaccine efficacy among HIV-positive women is currently unknown, the present 
analysis examined HPV vaccination as an exploratory analysis across a broad range of 
inputs. With the assumption that the vast majority of women will acquire HPV prior to 
HIV diagnosis (given that HPV is both common and highly transmissible), as an upper 
bound vaccine efficacy (VE) was estimated based on observed protective effects in HIV-
negative women with likely prior or current HPV infection (i.e. adult, HPV seropositive, 
or HPV DNA positive women) (Table 10). Protective effects have been observed in this 
population for both vaccine and non-vaccine HPV types; thus, separate estimates of 
efficacy were applied to transitions for exiting Normal to HPV-16/18 states and Normal 
to HPV-Other states. Due to limited vaccine type specific efficacy data among this 
population, vaccination was simulated generically. No therapeutic benefits were assumed 
for those infected with HPV at baseline of the simulation. Upper bound estimates of 
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efficacy were reduced incrementally to collectively capture uncertainty, as well as the 
likely effects of reactivation and reduced vaccine efficacy in HIV-positive women. 
Vaccination uptake was set at 100% with complete coverage for all three-doses, with 
duration of immunity varied from 10 to 15 years.  
E3.2 Calibration 
In the absence of estimates of cervical cancer risk specific to HIV-positive 
populations, the natural history model was calibrated to 2012 GLOBOCON estimates for 
Senegal [61] with a multiplier ranging from two to eight to capture the relative effect of 
HIV as reported in the literature [3, 88, 103-106, 180, 181]. The Nelder-Mead direct-
search algorithm [182, 183] with 10,000 initial value combinations was employed to 
minimize sums of squares between simulation outcomes and calibration targets. Natural 
history estimates which best optimized model fit and were biologically relevant were 
selected (e.g. risk of progression to cancer was greater for HPV-16/18 than HPV-Other 
with HPV-16/18 accounting for approximately 70% of cervical cancer) [11, 130]. Inputs 
for the base analysis were calibrated for a five-fold increase in cervical cancer risk with 
the top ten percent of best fitting estimates for two- to eight-fold increases forming the 
lower and upper bounds, respectively, for sensitivity analyses. To assess internal validity 
of the natural history model, outputs were compared to reported HPV and CIN2/3 
prevalence from studies used to estimate natural history transitions with high agreement 
observed [3]. Model outputs were also compared to literature from the broader area of 
SSA to assess external validity. Specifically, prevalence of HPV [92, 93], HR-16/18 
[184], and high-grade lesions [185], as well as HPV-16/18 positivity among women with 
high-grade lesions [96] were compared with high agreement observed between study 
results and model output. Lastly, the model was reviewed by Senegalese clinicians 
providing care to HIV-positive women to ensure face-validity of key inputs, outputs, and 
assumptions. Calibration was conducted using R Studio 3.1 (Boston, MA, USA). 
E3.3 Analysis 
The relative performance of each prevention strategy was measured using incremental 
cost-effectiveness ratios (ICERs) which represent the cost of an additional unit of 
effectiveness that is obtained when implementing a more effective strategy rather than a 
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less effective strategy. Strategies that were more costly and less effective than another 
(i.e. strongly dominated) and strategies with a higher ICER than a more effective 
alternate strategy (i.e. weakly dominated) were eliminated. Based on World Health 
Organization recommendations, strategies with ICERs less than Senegal’s 2013 per 
capita Gross Domestic Product (GDP) were considered ‘very cost-effective’ 
(approximately I$1,050) and strategies less than three times the per capita GDP were 
considered ‘cost-effective’ (approximately I$3,150) [5, 186]. One-way sensitivity 
analyses and tornado plots were conducted to assess the influence of uncertainty in key 
parameters on results. Future costs and life years were discounted at an annual rate of 
3%. Markov cohort cost-effectiveness modeling was conducted in TreeAge Pro 2015 
(Williamstown, MA, USA). IRB approval was not necessary for this study as the existing 
data do not meet the criterion for human subjects’ research. 
 
E4. Results 
E4.1 Base analysis (Table 11) 
With no screening or vaccination, discounted fifteen year costs per woman and life 
expectancy were I$66 and 9.55 years, respectively (costs accrued under a no screening 
paradigm are the result of women seeking medical care given presentation of cervical 
cancer symptoms). With duration of immunity extending for 15 years, vaccination 
coupled with VIA screening was ‘very cost-effective’ for all vaccine efficacy (VE) 
scenarios examined with vaccine costs set at I$5, and under an optimal VE scenario (i.e. 
transitions to HPV-16/18 states and HPV-Other states reduced by 80% and 50%, 
respectively) with vaccine costs set at ≤I$31. With costs ≥I$31 and VE reduced to 
account for likely diminished effectiveness among adult HIV-positive women, 
vaccination alone became dominated through extension with a higher incremental cost-
effectiveness ratio than VIA screening. Specifically, with costs ≥I$31 vaccination was 
dominated when VE fell below approximately 70% and 40% for reducing transitions to 
HPV-16/18 and HPV-Other states, respectively (or similar combinations of strata specific 
VE that yield the same overall reductions in transitions). Overall, vaccination becomes 
dominated through extension when costs exceed I$38, I$24, I$15, and I$7 for each of the 
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four levels of VE examined, respectively. Domination through extension applies when a 
strategy is less costly but also less effective than an alternative strategy, to such a degree 
that the cost per life year saved is greater than a more costly and more effective option. 
Similar patterns in relative cost-effectiveness remained when duration of immunity was 
reduced to 10 years.  
E4.2 Sensitivity analyses (Table 12) 
One-way sensitivity analyses with duration of immunity and vaccine costs set at 15 
years and I$31, respectively, revealed that estimates of cost-effectiveness were most 
influenced by death from other causes, discounting, and the specificity of VIA. However, 
relative cost-effectiveness remained stable across several input parameters such that 
vaccination with optimal efficacy coupled with VIA screening remained ‘very cost-
effective’ (except with maximum discounting and death from other causes in which 
ICERs slightly exceeded the WTPT for ‘very cost-effective’). Vaccination with minimal 
efficacy remained dominated by extension when varying all inputs examined. Notably, 
with the maximum specificity of VIA (89%) vaccination becomes dominated even with 
optimal VE, highlighting the costly implications of false-positives. Reductions in the 
initial prevalence of HPV (i.e. increased initial parameterization for Normal) lead to 
increased cost-effectiveness of vaccination as a greater proportion of women could 
immediately benefit from vaccination. 
When examining the impact of uncertainty using tornado plots (Figure 9), vaccine 
costs, VE for HPV-16/18, the specificity of VIA, and death from other causes emerge as 
the most consistently influential input variables. VE for transitions to HPV-Other states, 
retention in follow-up LEEP care, VIA sensitivity, and cryotherapy effectiveness were 
less influential. 
 
E5. Discussion 
The objective of this simulation model was to provide insight into the potential 
impact of HPV vaccination in the high-risk population of HIV-positive women in 
Senegal. This model found that vaccination was only a cost-effective option under 
optimal vaccine efficacy and/or costing scenarios. Results were largely driven by relative 
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differences in costs as the impact on life expectancy of the cervical cancer prevention 
strategies examined was minimal due to high rates of all-cause mortality among HIV-
positive women in SSA. Recent efforts to subsidize HPV vaccination cost hold promise; 
however, GAVI funding for HPV vaccination is specific to adolescent girls such that 
vaccine costs for HIV-positive adult women will likely exceed that of the subsidized 
series. Importantly, efforts to develop vaccines with less dependence on cold-chain 
storage and distribution are underway, which, if successful, could greatly reduce the cost 
and infrastructural requirements for HPV vaccination [207].  
We used reported vaccine efficacy among previously HPV infected patients to 
provide a theoretical upper bound for the relative impact of vaccination among HIV-
positive women. This literature is extremely limited with significant heterogeneity in 
methodology (e.g. vaccine type, dosage, endpoints, and underlying study population with 
regards to age and prior infection). These analyses were post-hoc, with limited statistical 
power, and significant variability in reported estimates. In light of these factors, the 
potential impact of vaccination was modeled generically (in other words, differences in 
efficacy for bivalent, quadrivalent and nonavalent vaccines were not examined due to a 
lack of data). Further, previously HPV infected HIV-negative women likely present over 
estimates of efficacy as they are immunocompetent and capable of mounting an immune 
response such that they became seropositive. HIV-positive women may be less capable of 
both mounting and maintaining an immune response; thus, the capacity to extrapolate 
effects observed in previously HPV infected HIV-negative samples to HIV-positive 
women remains unknown. For instance, vaccination of HIV-positive individuals against 
Hepatitis A, Hepatitis B, Hepatitis C, influenza, pneumococcus, diphtheria, pertussis, 
tetanus, haemophilus influenza, and cholera elicit lower immune responses than in HIV-
negative individuals [208-228]. Further, HPV-16/18 titer levels among those with HIV 
have been shown to be 23% to 70% lower than HIV-negative controls [52, 53]. 
Importantly, responses among those on ART often remain sub-optimal relative to HIV-
negative individuals, although they have in some cases been shown to improve with 
larger and/or more frequent vaccine doses [203, 208]. Finally, the potential impact of 
reactivation on HPV vaccination efficacy is largely unknown as no therapeutic benefits 
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have been demonstrated; however, vaccine-induced immune responses could improve 
immune responses to reactivation. These factors should be considered when interpreting 
results. 
There are several limitations to this analysis. The present model does not account for 
indirect protective effects of vaccination (i.e. reduced HPV transmission to sexual 
partners), which may result in an underestimate of vaccine cost-effectiveness. However, 
the assumption that indirect effects could result from vaccinating HIV-positive women is 
largely determined by two factors: the underlying prevalence of HIV and the presumption 
that there are in fact meaningful protective effects to pass on. Less than 1% of Senegalese 
women are HIV-positive and HPV vaccine efficacy among this population remains 
unknown [82]. Further, vaccine effectiveness is examined at an aggregate level; however, 
given prior HPV exposure at the time of vaccination, CD4+ count, and ART use there 
may be underlying heterogeneity within the HIV-positive population which should be 
considered when generalizing results [53]. For instance, based on evidence that vaccine 
induced titers levels may be greater among those on ART [202], delaying vaccination 
could be considered among women with low CD4+ counts at the time of diagnosis until 
immune reconstitution has been achieved with treatment. The present model is also 
ageless and assumes HPV vaccination at time of HIV diagnosis (i.e. a point-of-care 
approach). There is sparse literature reporting the average age at time of HIV diagnosis, 
with the majority of literature regarding HIV testing focusing on CD4+ count and other 
indicators of disease progression at time of diagnosis. The average age of the underlying 
cohort used to estimate natural history transitions was 34 years. Estimates of life 
expectancy for HIV-positive women in SSA are highly varied. Based on an analysis of 
fourteen multinational HIV-positive cohort studies, it was found that life expectancy is 
highly dependent on CD4+ count at time of ART initiation, as well as continued access 
and adherence to ART, with an average life expectancy in those with HIV approximately 
two-thirds that of HIV-negative controls [229, 230]. ART coverage in Senegal is 
currently estimated at approximately 50% [65] and testing strategies target high-risk 
populations (such as commercial sex workers) which may overlook key sub-populations 
(such as married women in polygamous relationships) resulting in heterogeneity in age at 
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time of HIV diagnosis. Given these factors, the impact of the time horizon chosen for 
present analysis was examined (results not shown) with vaccination becoming more cost-
effective with an extended time horizon; however, there were no meaningful changes to 
relative comparisons of cost-effectiveness. Lastly, the present cost-effectiveness model is 
based on the inclusion of factors directly related to cervical cancer with the assumption 
that all background variables are held constant (referred to as the steady-state 
assumption). In reality, there are many dynamic variables that can impact results across 
time and space (such as civil unrest, natural disasters, global warming and changes in 
economic stability).  
 
E6. Conclusion 
With lower vaccine-induced titer levels reported among adult HIV-positive women 
and a potential corresponding reduction in vaccine efficacy, HPV vaccination costs must 
be reduced for primary prevention to be cost-effective in comparison to screening. Efforts 
to implement targeted screening, reduce the cost of HPV vaccination, develop therapeutic 
vaccines, and evaluate upcoming HPV antiviral treatments should be made for this high-
risk population.  
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F. CONTRIBUTIONS AND CONCLUSIONS 
 
This research involves the synthesis of epidemiologic data and methodologies from 
several public health disciplines. Key contributions are discussed below. 
Quantifying the natural history of HPV among women in the high-risk setting of 
SSA, using a large sample and providing direct comparisons between HIV-positive and 
HIV-negative women, represents a major contribution to the field. HIV-positive women 
were found to depart from their HIV-negative counterparts at each stage of the natural 
history, providing unique insight in the pathophysiology of HPV among HIV-positive 
women and evidence that sustained prevention measures are needed. Importantly, natural 
history estimates provide the foundation for simulation modeling such that this work 
directly supports the development of simulation models. Estimates are presented in two 
formats (unadjusted in AIM I and stratified by HPV type in AIM II). These data allow 
other research teams from around the world to create cervical cancer prevention models 
tailored to different settings and different sub-populations of HIV-positive women. With 
independent teams constructing models based on different assumptions, model structures, 
and background target populations comes a more robust understanding of cost-effective 
prevention. 
With clear evidence that HIV-positive women are at an increased risk of cervical 
cancer the following research questions were addressed: given high competing risks 
among HIV-positive women (i.e. high overall mortality) can cervical cancer interventions 
yield meaningful effects, and if so, what is the optimal strategy based on cost-
effectiveness and the context of medical care infrastructure within Senegal and the more 
general low resource setting of SSA. This research demonstrated that cervical cancer 
screening can yield meaningful improvements in life expectancy such that VIA screening 
is ‘very cost-effective’ based on WHO criterion. For instance, the discounted average 
increased life expectancy of 1.7 resulting from annual VIA yields approximately 2,830 
additional life years among the estimated 20,000 HIV-positive women in the Senegal. 
This analysis represents the first cost-effectiveness analysis of cervical cancer screening 
among HIV-positive women in Africa, with comprehensive comparisons of several 
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different screening strategies. This model was developed for the context of Senegal; 
however, given the demonstrated stability of findings in sensitivity analyses and sound 
biological exchangeability of natural history estimates, there may be a reasonable 
foundation upon which to generalize findings to SSA nations with similar economic and 
social characteristics. 
With ongoing efforts to expand HPV vaccine coverage and subsidize costs for 
adolescent girls in low resource settings, the potential application to HIV-positive women 
is of growing interest. This research demonstrated that targeted HPV vaccination among 
HIV-positive women was only cost-effective in comparison to screening under optimal 
vaccine efficacy and costing scenarios. Given lower vaccine-induced titer levels reported 
among adult HIV-positive women and a potential corresponding reduction in vaccine 
efficacy, vaccination costs must be reduced for primary prevention to be cost-effective.  
Importantly, the simulation model developed for AIM II and AIM III uses a 
conditional framework in that cost-effectiveness is examined within a specific disease 
(cervical cancer). With increased computational capacities, the field of decision analysis 
is now developing approaches for examining cost-effectiveness across diseases and 
populations. This represents a major methodological advancement in that head-to-head 
comparisons across models can be made. When accounting for high competing risks 
among this population, it is possible that while cervical cancer screening is cost-effective, 
other interventions are more cost-effective (for example, efforts to expand HIV testing, 
manage chronic tuberculosis, etc.). This methodological advancement represents an 
exciting opportunity with great potential to effect change and better optimize resource 
allocation. Efforts to work collaboratively with other decision modeling teams will be 
made to address this limitation and advance the field. 
In summary, this research capitalizes on extensive existing data from Senegal, 
uniquely examines both primary and secondary prevention strategies, and provides a 
platform for future research endeavors. Key findings indicate that efforts should be made 
to implement targeted screening, reduce the cost of HPV vaccination, develop therapeutic 
vaccines, and evaluate upcoming HPV antiviral treatments for this high-risk population.
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Table 1.  Abbreviations 
 
ADE AIDS defining event 
AIDS acquired immune deficiency syndrome 
AIS adenocarcinoma in situ 
ART anti-retroviral therapy 
ASCUS atypical squamous cells of undetermined significance 
CDC Centers of Disease Control and Prevention 
CEA cost-effectiveness analysis 
CEAC cost-effectiveness acceptability curve 
CIN cervical intraepithelial neoplasia 
CPI consumer price index 
CSW commercial sex worker 
GDP gross domestic product 
EGL external genital lesions 
HC2 Hybrid Capture 2 
HIV human immunodeficiency virus 
HPV human papillomavirus 
HR-HPV high-risk HPV 
HSIL high-grade squamous intraepithelial lesion 
ICC invasive cervical cancer 
ICER incremental cost-effectiveness ratios 
ITT intention-to-treat 
LEEP loop electrosurgical excision procedure 
LR-HPV low-risk HPV 
LSIL low-grade squamous intraepithelial lesion 
OIs opportunistic infections 
PCR polymerase chain reaction 
PEPFAR President’s Emergency Plan for AIDS Relief 
PPP purchasing power parity 
RCT randomized controlled trials 
SSA sub-Saharan Africa 
SVA single visit approach 
TVC total vaccinated cohort (regardless of HPV-seropositivity) 
US United States 
VC vaccine cost 
VE vaccine efficacy 
VIA visual inspection wit acetic acid 
WHO World Health Organization 
WTPT willingness-to-pay threshold 
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Table 2.  Overview of studies included in the analysis 
 
No. 
Study  
Title 
Study  
duration 
Inclusion 
criteria 
Study  
sample* 
Type-specific HPV 
DNA detection  
Relevant 
references 
1 Natural history of cervical 
neoplasia  in HIV-1 and HIV-2 
1994 - 1999 Age ≥15 755        
(291 HIV+) 
12 types up to 1998 
27 types thereafter 
[3, 122, 136] 
2 Control of HIV-1 by HIV-2 
associated immune responses 
2000 - 2006 Age ≥15 
ART naïve 
121  
(119 HIV+) 
38 types [139] 
3 Epidemiology of HIV-1/HIV-2 
dual infection 
2001 - 2005 Age ≥15 
HIV-1/2+  
On ART 
7  
(7 HIV+) 
38 types [140] 
4 Developing new approaches 
for cervical cancer control 
2002 - 2007 Age ≥15 3  
(3 HIV+) 
38 types [137] 
5 Antiretroviral therapy for 
HIV-2 infection in Senegal 
2005 - ongoing Age ≥16 
HIV-2+ 
On ART 
4  
(4 HIV+) 
38 types [138] 
6 HIV-associated DNA hyper-
methylation in cervical cancer 
2005 - 2010 Age ≥18 387  
(151 HIV+) 
38 types [67, 141] 
* Sample size for the present study differs from the total samples reported in prior publications due to missing HIV status 
and/or the lack of longitudinal cytology/histology and HPV DNA data. 
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Table 3.  Baseline characteristics of pooled study sample 
 
Characteristic 
HIV- 
(n = 702) 
HIV+ 
(n = 575) 
Total 
N = 1,277 
Age (years)    
Median 34 35 34 
Interquartile range 27-44 29-41 28-42 
Age at sexual debut (years)    
Median 17 17 17 
Interquartile range 15-19 15-19 15-19 
Lifetime sex partners (%)    
None 0.6 0.2 0.4 
One 45.5 31.2 39.0 
2-5 25.2 32.8 28.6 
6-10 1.7 1.9 1.8 
>10 27.0 33.9 30.2 
Religion (%)    
Muslim  85.5 88.9 87.1 
Christian 14.1 10.6 12.4 
Other/None 0.4 0.5 0.5 
Marital status (%)    
Married (monogamy) 34.4 24.8 30.1 
Married (polygamy)   25.5 14.3 20.5 
Never married  15.4 9.4 12.7 
Separated/divorced  20.4 32.2 25.7 
Widowed  4.3 19.3 11.0 
Education (%)    
None 42.6 50.5 46.1 
Primary School 30.1 32.9 31.4 
Secondary School 24.3 15.5 20.4 
University 3.0 1.1 2.1 
Follow-up duration (days)    
Median 780 808 791 
Interquartile range 368-1,155 386-1,330 377-1,213 
Interval between clinic visits (days)    
Median 139 134 136 
Interquartile range 122-232 119-238 120-236 
Commercial sex worker (%) 24.8 32.5 28.3 
Cigarette use (%, ever) 15.4 19.5 17.2 
Contraception use (%, ever) 46.9 37.1 42.5 
Alcohol consumption (%, ever) 9.0 14.6 11.5 
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Table 3.  continued… 
 
 
Characteristic 
HIV- 
(n = 702) 
HIV+ 
(n = 575) 
Total 
N = 1,277 
HIV-positive subsample    
HIV-subtype (%)    
HIV-1  - 68.0 - 
HIV-2 - 23.0 - 
Dual infection - 9.0 - 
CD4+ count (cells/µL)    
Median - 416 - 
Interquartile range - 257-633 - 
ART use (%, ever) - 27.2 - 
AIDS a (%) - 24.0 - 
a: Classified by a defining event or CD4+ count < 200 recorded at any time during follow-
up. 
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Table 4.  Hazard ratios for HIV+ and HIV- Senegalese women 
 
 Transition Health Stages 
Initial Health Stages  HPV  HSIL 
 Total n Hazard ratio P-value  n Hazard ratio P-value 
Normal  1054 503    28   
         
HIV+ 484 289 1.62 <0.0001  17 1.60 0.21 
HIV- 570 214 ref. -  11 ref. - 
         
Incident Classification 594 295 1.64 <0.0001  18 1.69 0.17 
Prevalent Classification 460 208 ref. -  10 ref. - 
  Normal  HSIL 
 Total n Hazard ratio P-value  n Hazard ratio P-value 
HPV  1233 752    122   
         
HIV+ 602 296 0.47 <0.0001  83 2.57 <0.0001 
HIV- 631 456 ref. -  39 ref. - 
         Incident Classification 489 321 1.85 <0.0001  50 0.87 0.46 
Prevalent Classification 744 431 ref. -  72 ref. - 
  Normal  HPV 
 Total n Hazard ratio P-value  n Hazard ratio P-value 
HSIL 168 24    113   
         
HIV+ 106 13 0.59 0.21  76 1.18 0.45 
HIV- 62 11 ref. -  37 ref. - 
         
Incident Classification 105 16 1.39 0.43  69 0.92 0.68 
Prevalent Classification 63 8 ref. -  44 ref. - 
*Note: Transition numbers (by row) do not sum to the total provided as women remained in the same state for the 
duration of follow-up or transitioned to cervical cancer. Transitions to cancer were not examined due to extremely 
limited sample sizes. 
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Table 5.  Univariate analyses of potential effect modifiers, HIV+ women 
 
 Transition Health Stages 
Initial Health Stages  HPV  HSIL 
 
Total n 
Hazard 
ratio 
P-value  n 
Hazard 
ratio 
P-value 
Normal          
         
CD4+ count < 200 48 27 1.31 0.22  4 3.31 0.03 
CD4+ count ≥ 200 412 257 ref. -  13 ref. - 
         
HPV - 16/18 26 23 0.96 0.86  3 4.67 0.04 
HPV - Other 200 183 ref. -  5 ref. - 
         
HPV - Multiple Types 67 60 1.99 <0.0001  3 2.07 0.31 
HPV - Single Type 272 146 ref. -  5 ref. - 
         
Age ≤ 25  68 46 1.51 0.01  1 0.39 0.37 
Age > 25 414 242 ref. -  16 ref. - 
         
HIV-1 316 205 1.85 <0.0001  8 0.41 0.06 
HIV-2 130 65 ref. -  9 ref. - 
  Normal  HSIL 
 
Total n 
Hazard 
ratio 
P-value  n 
Hazard 
ratio 
P-value 
HPV          
         
CD4+ count < 200 101 32 0.54 0.003  22 2.23 0.005 
CD4+ count ≥ 200 466 257 ref. -  56 ref. - 
         
HPV - 16/18 170 29 0.36 <0.0001  30 2.05 0.0059 
HPV - Other 449 178 ref. -  41 ref. - 
         
HPV - Multiple Types 306 63 0.36 <0.0001  48 2.29 0.0016 
HPV - Single Type 313 144 ref. -  23 ref. - 
         
Age ≤ 25  87 46 1.26 0.22  13 1.13 0.73 
Age > 25 514 249 ref. -  70 ref. - 
         
HIV-1 425 192 0.74 0.03  63 1.83 0.08 
HIV-2 131 82 ref. -  12 ref. - 
*Transition numbers (by row) do not sum to total as some women remained in the same state for the 
duration of follow-up. HPV-type specific analyses from transitions from Normal (the initial state) were 
conducted based on the type acquired, while analyses of transitions from HPV (the initial state) were 
conducted based on what type women had while HPV+. 
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Table 6.  Key model parameters for base-case and sensitivity analyses 
 
Parameter Base Minimum Maximum References 
Natural history, 4-month     
Progression     
Normal to HPV-16/18 0.0247 0.0159 0.0385 [171] 
Normal to HPV-Other 0.1548 0.1323 0.1847 [171] 
Normal to CIN2/3-16/18 0.0026 0.0008 0.0089 [171] 
Normal to CIN2/3-Other 0.0041 0.0016 0.0106 [171] 
HPV-16/18 to CIN2/3-16/18 0.0439 0.0291 0.0674 [171] 
HPV-Other to CIN2/3-Other 0.0226 0.0163 0.0316 [171] 
HPV-16/18 to HPV-Other 0.1053 0.0786 0.1445 [171] 
HPV-Other to HPV-16/18 0.0465 0.0358 0.0607 [171] 
CIN2/3-16/18 to ICC Early 0.1065 0.0335 0.1680 [171, 231]a 
CIN2/3-Other to ICC Early 0.0160 0.0084 0.0440 [171, 231]a 
ICC Early to ICC Lateb 0.1517 0.1062 0.1972 [231, 232] 
Regression     
HPV-16/18 to Normal 0.0536 0.0388 0.0748 [171] 
HPV-Other to Normal 0.1252 0.1074 0.1474 [171] 
CIN2/3-16/18 to HPV-16/18 0.4000 0.3500 0.4500 [171]a 
CIN2/3-Other to HPV-Other 0.4500 0.4000 0.5000 [171]a 
CIN2/3-16/18 to Normal 0.0050 0.0010 0.0100 [171]a 
CIN2/3-Other to Normal 0.0582 0.0273 0.1268 [171] 
Mortality     
Other causes 0.0125 0.0050 0.0200 [81, 172-174] 
Early ICCb 0.0431 0.0302 0.0561 [231, 233] 
Late ICCb 0.1216 0.0852 0.1581 [231, 234] 
Symptoms of Late ICC 0.4200 0.2600 0.6600 [231, 232] 
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Table 6.  continued… 
 
Parameter Base Minimum Maximum References 
Screening validity     
Rapid HPV, sensitivity 0.82 0.74 0.90 [167, 235, 236] 
Rapid HPV, specificity 0.64 0.51 0.77  
HC2, sensitivity 0.90 0.84 0.95 [135, 237-240]  
HC2, specificity 0.64 0.51 0.77  
Cytology, sensitivity 0.73 0.53 0.93 [231, 237, 238, 240-244] 
Cytology, specificity 0.73 0.49 0.96  
VIA, sensitivity 0.75 0.63 0.87 [135, 237, 238, 240, 242, 244-246] 
VIA, specificity 0.70 0.51 0.89  
Treatment effectiveness, %     
Pre-cancer treatment 80.0 60.0 90.0 [125, 135, 187, 188, 239, 247-260] 
Retention in care 100.0 50.0 100.0 [177-179, 248, 261-263] 
Costs, 2013 I$     
Rapid HPV DNA testing 24 5 42 [264] 
HC2 HPV DNA testing 22 12 31 [194, 265-267] 
Cytology 10 4 16 [194, 265-268] 
VIA 5 2 8 [169, 265-267, 269] 
Cryotherapy 53 15 90 [169, 265-267, 269] 
LEEP 164 47 280 [265-267] 
Hysterectomy 540 324 755 [265-267] 
Palliative care 200 121 280 [270, 271] 
a: Estimated using statistical calibration with initial values from the Senegal data.  
b: Variation assumed to be ±30% of the base-case value. 
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Table 7.  Cost-effectiveness of cervical cancer screening strategies in HIV+ Senegalese women  
 
Strategy 
Cost 
2013 I$ 
Life  
years 
ICER* 
Cancer 
incidence 
Cancer 
death 
False 
positivesa 
False 
negativesa 
Over referral 
to treatmenta 
Baseline screening 
No screening 66 9.555 reference 0.071941 0.048573 - - - 
VIA 101 9.606 681 0.066442 0.040406 554 22 554 
Cytology 106 9.606 dom 0.066562 0.040465 498 24 498 
Rapid HPV/VIA triage 123 9.603 dom 0.067278 0.040824 862 35 199 
Rapid HPV/cytology 
triage 
126 9.603 dom 0.067384 0.040878 842 37 179 
HC2 140 9.609 14,863 0.065592 0.039999 666 9 666 
Rapid HPV 144 9.607 dom 0.066035 0.040209 665 16 665 
Baseline and 5 year screening 
VIA 110 9.628 610 0.064400 0.034034 780 30 780 
Cytology 117 9.627 dom 0.064574 0.034124 702 32 702 
Rapid HPV/VIA triage 140 9.624 dom 0.065603 0.034664 1,215 47 280 
Rapid HPV/cytology 
triage 
144 9.624 dom 0.065754 0.034743 1,187 49 252 
HC2 164 9.631 15,153 0.063142 0.033384 938 12 938 
Rapid HPV 169 9.629 dom 0.063802 0.033724 937 21 937 
Baseline, 5, and 10 year screening 
VIA 119 9.631 698 0.062716 0.030744 962 36 962 
Cytology 127 9.630 dom 0.062936 0.030851 866 39 866 
Rapid HPV/VIA triage 154 9.627 dom 0.064224 0.031487 1,498 56 346 
Rapid HPV/cytology 
triage 
158 9.627 dom 0.064412 0.031580 1,464 59 311 
HC2 182 9.635 17,110 0.061120 0.029969 1,156 14 1,156 
Rapid HPV 188 9.633 dom 0.061961 0.030376 1,155 25 1,155 
Baseline and triennial screening 
VIA 150 9.652 873 0.058424 0.025095 1,523 54 1,523 
Cytology 162 9.651 dom 0.058756 0.025227 1,371 59 1,371 
Rapid HPV/VIA triage 202 9.647 dom 0.060696 0.026002 2,372 85 547 
Rapid HPV/cytology 
triage 
208 9.647 dom 0.060977 0.026115 2,317 88 493 
HC2 244 9.656 21,183 0.055982 0.024130 1,832 21 1,832 
Rapid HPV 253 9.654 dom 0.057274 0.024639 1,830 39 1,830 
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Table 7.  continued…  
 
 
Strategy 
Cost 
2013 I$ 
Life  
years 
ICER* 
Cancer 
incidence 
Cancer 
death 
False 
positivesa 
False 
negativesa 
Over referral 
to treatmenta 
Baseline and annual screening 
VIA 273 9.693 1,500 0.042742 0.014773 3,637 115 3,637 
Cytology 300 9.692 dom 0.043430 0.014933 3,271 124 3,271 
Rapid HPV/VIA triage 388 9.688 dom 0.047476 0.015876 5,653 180 1,304 
Rapid HPV/cytology 
triage 
402 9.687 dom 0.048065 0.016014 5,520 188 1,174 
HC2 489 9.698 41,195 0.037716 0.013604 4,380 45 4,380 
Rapid HPV 509 9.695 dom 0.040366 0.014220 4,372 82 4,372 
*Incremental cost-effectiveness ratios were not presented for those strategies that were dominated (i.e. more costly and less effective than 
another). 
a: per 1,000 women screened over the course of 15 years (women may experience false positives, false negatives, and over referrals to treatment 
more than once in those scenarios in which screening is recurrent). 
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Table 8.  One-way sensitivity analyses for cost-effectiveness of cervical cancer screening strategies in 
HIV+ Senegalese women 
 
 Incremental cost-effectiveness ratio 
Input variable VIA Cytology 
Rapid 
HPV/ 
VIA 
Rapid 
HPV/ 
Cytology 
HC2 
Rapid 
HPV 
Base case 698 dom dom dom 17,110 dom 
Retention       
Minimum, 0.5 1,100 640 dom dom dom 41,447 
Base, 1.0 698 dom dom dom 17,110 dom 
Progression to cervical cancer       
Minimum, 16/18: 0.0335, Other: 0.0084 1,425 dom dom dom 41,229 dom 
Maximum, 16/18: 0.1680, Other: 0.0440 414 dom dom dom 11,206 dom 
Discounting       
Minimum, 0.00 508 dom dom dom 13,722 dom 
Maximum, 0.05 852 dom dom dom 19,791 dom 
Death – other causes       
Minimum, 0.005 555 dom dom dom 14,563 dom 
Maximum, 0.020 872 dom dom dom 20,144 dom 
Pre-cancer treatment effectiveness       
Minimum, 0.6 772 dom dom dom 20,236 dom 
Maximum, 0.9 666 dom dom dom 16,255 dom 
Cervical cancer mortality       
Minimum, Early: 0.0302, Late: 0.0561 1,056 dom dom dom 25,037 dom 
Maximum, Early: 0.0852, Late: 0.1581 653 dom dom dom 15,544 dom 
Potential impact of ART uptake         
Low ART: Maximum progression/death, minimum regression 237 dom dom dom 6,906 dom 
High ART: Minimum progression/death, maximum regression 2,298 dom dom dom 82,378 dom 
*Based on three total screens (baseline with five and ten year screenings) 
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Table 9.  Model parameters for base-case and sensitivity analyses  
 
Parameter Base Minimum Maximum References 
Initial vector, %a     
Normal 34.86 27.89 41.83 [171] 
   HPV-16/18 14.87 11.89 17.84 [171] 
HPV-Other 42.91 34.33 51.49 [171] 
CIN2/3-16/18 2.39 1.91 2.87 [171] 
CIN2/3-16/18 3.59 2.87 4.30 [171] 
ICC 0.69 0.55 0.83 [171] 
Natural history, 4-month risk     
Progression      
Normal to HPV-16/18 0.0247 0.0159 0.0385 [171] 
Normal to HPV-Other 0.1548 0.1323 0.1847 [171] 
Normal to CIN2/3-16/18 0.0026 0.0008 0.0089 [171] 
Normal to CIN2/3-Other 0.0041 0.0016 0.0106 [171] 
HPV-16/18 to CIN2/3-16/18 0.0439 0.0291 0.0674 [171] 
HPV-Other to CIN2/3-Other 0.0226 0.0163 0.0316 [171] 
HPV-16/18 to HPV-Other 0.1053 0.0786 0.1445 [171] 
HPV-Other to HPV-16/18 0.0465 0.0358 0.0607 [171] 
CIN2/3-16/18 to ICC Early 0.1065 0.0335 0.1680 [171, 231]b 
CIN2/3-Other to ICC Early 0.0160 0.0084 0.0440 [171, 231]b 
ICC Early to ICC Latec 0.1517 0.1062 0.1972 [231, 232] 
Regression      
HPV-16/18 to Normal 0.0536 0.0388 0.0748 [171] 
HPV-Other to Normal 0.1252 0.1074 0.1474 [171] 
CIN2/3-16/18 to HPV-16/18 0.4000 0.3500 0.4500 [171]b 
CIN2/3-Other to HPV-Other 0.4500 0.4000 0.5000 [171]b 
CIN2/3-16/18 to Normal 0.0050 0.0010 0.0100 [171]b 
CIN2/3-Other to Normal 0.0582 0.0273 0.1268 [171] 
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Table 9.  continued…  
 
Parameter Base Minimum Maximum References 
Natural history, 4-month risk 
Mortality     
Other causes 0.0125 0.0050 0.0200 [81, 172-174]. 
Early ICCc 0.0431 0.0302 0.0561 [231, 233] 
Late ICCc 0.1216 0.0852 0.1581 [231, 234] 
Symptoms of Late ICC 0.4200 0.2600 0.6600 [231, 232] 
Vaccine efficacy, %     
HPV-16/18 states - 0.0 80.0 [272-276] 
HPV-Other states - 0.0 50.0  
Screening/treatment performance 
VIA, sensitivity 0.75 0.63 0.87 [135, 237, 238, 240, 242, 244-246] 
VIA, specificity 0.70 0.51 0.89  
Pre-cancer treatment 0.80 0.60 0.90 [125, 135, 187, 188, 239, 247-260] 
Costs, 2013 I$     
VIA 5 2 8 [169, 265-267, 269] 
Cryotherapy 53 15 90 [169, 265-267, 269] 
LEEP 164 47 280 [265-267] 
Hysterectomy 540 324 755 [265-267] 
Palliative care 200 121 280 [270, 271] 
HPV vaccination 31 5 57 [265, 266, 268, 277-279] 
a: Variation assumed to be ±20% of the base-case value. 
b: Estimated using statistical calibration with initial values from the Senegal data.  
c: Variation assumed to be ±30% of the base-case value. 
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Table 10.  Selected outcomes, HPV vaccine trials among HIV-negative women with prior HPV 
 
Study 
Study design, 
vaccine type 
Age, 
follow-up 
Inclusion  
criteria 
Vaccine  
Efficacy 
Main  
conclusions 
      
Lehtinen et al.[272] RCT, doubled-blinded, 
Bivalent 
(N=17,402) 
15-25, 
48 mo. 
(median) 
Women with 
 ≤ 6 lifetime 
sex partners, 
TVC 
60.7% reduction in in HPV-16/18 CIN2+ 
(80.1% vs. 33.2% in 15-17 and 21-25 year olds) 
 
33.1% reduction in in total CIN2+ 
(44.0% vs. 8.9% in 15-17 and 21-25 year olds) 
 
Effectiveness in adult 
women which reduced 
with increasing age (i.e. 
inversely associated) 
Castellsague et 
al.[273] 
RCT, double-blinded, 
Quadrivalent 
(N= 3,819) 
24-45, 
48 mo. 
(median) 
Women at 
least 5 years 
free of cervical 
disease or 
genital warts 
66.9% reduction in persistent infection (6 mo.), 
CIN or EGL among HPV-6/11/16/18 seropositive 
and DNA-negative women 
 
47.2% reduction in persistent infection (6 mo.), 
CIN or EGL among ITT sample 
 
Effectiveness in adult 
women, seropositivity is an 
underestimate of prior 
exposure likely producing 
over estimates of VE 
Szarewski et al. [274] Sub-analysis of RCT, 
double-blinded, 
Bivalent 
(N= 3,489) 
15-25, 
39 mo. 
(median) 
HPV-16/18 
seropositive 
and DNA-
negative 
women 
49.7% reduction in HPV-16/18 infection 
 
87.8% reduction in HPV-16/18 CIN1+ 
88.5% reduction in HPV-16/18 CIN2+ 
 
67.2% reduction in total CIN1+ 
68.8% reduction in total CIN2+ 
 
Effectiveness in women with 
serological indications of 
prior infection 
Joura et al. [275] Retrospective analysis 
of RCT, double-
blinded, Quadrivalent 
(N= 1,350) 
 
15-26, 
16 mo. 
(median) 
Women who 
received 
treatment for 
cervical pre-
cancer 
74.2% reduction in HPV-6/11/16/18 CIN1+ 
61.3% reduction in HPV-6/1116/18 CIN2+ 
 
48.3% reduction in total CIN1+ 
64.9% reduction in total CIN2+ 
Effectiveness in women 
with prior treatment for 
cervical pre-cancer 
FUTURE II Study 
Group[276] 
Sub-analysis of two 
RCTs, double-blinded, 
Quadrivalent 
(N= 3,489) 
15-26, 
36 mo. 
(median) 
Women with  
≤ 4 lifetime 
sex partners 
and no genital  
10.6% reduction in HPV-16/18 CIN2+ or AIS 
among women who were HPV-16/18 seronegative, 
DNA positive at baseline 
 
1.2% reduction in HPV-16/18 CIN2+ or AIS 
among women who were HPV-16/18 seropositive, 
DNA positive at baseline 
 
No meaningful 
effectiveness in women 
with evidence of former or 
current infection at baseline 
RCT, randomized controlled trials; CIN, cervical intraepithelial neoplasia; EGL, external genital lesions; ITT, intention-to-treat; TVC, total vaccinated 
cohort (regardless of HPV-seropositivity); VE, vaccine efficacy; AIS, adenocarcinoma in situ 
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Table 11.  Vaccination in HIV+ Senegalese women, exploratory cost-effectiveness analysis of efficacy 
 
  Cost 2013 I$ Life 
Years 
ICER Cancer 
Incidence 
Cancer 
Death Strategy VC-5 VC-15 VC-31 VC-57 VC-5 VC-15 VC-31 VC-57 
Duration of immunity - 15 years 
VE - 80% HPV-16/18, 50% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 dom ref. ref. ref. 0.071941 0.048573 
  Vaccination 57 67 83 109 9.590 ref.b 39 498 ex. dom 0.049864 0.037723 
  VIA 119 119 119 119 9.631 dom ex. dom 866 698 0.062716 0.030744 
  Vaccination & VIA 114 124 140 166 9.653 907 907 985 2,191 0.044536 0.024347 
VE - 60% HPV-16/18, 30% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 Dom ref. ref. ref. 0.071941 0.048573 
  Vaccination 62 72 88 114 9.577 ref.b 285 ex. dom ex. dom 0.058228 0.041739 
  VIA 119 119 119 119 9.631 Dom ex. dom 698 698 0.062716 0.030744 
  Vaccination & VIA 118 128 144 170 9.645 819 819 1,763 3,612 0.051231 0.026651 
VE - 40% HPV-16/18, 20% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 dom. ref. ref. ref. 0.071941 0.048573 
  Vaccination 66 76 92 118 9.569 ref.b 694 ex. dom ex. dom 0.063541 0.044360 
  VIA 119 119 119 119 9.631 ex. dom 698 698 698 0.062716 0.030744 
  Vaccination & VIA 120 130 146 172 9.640 769 1,263 3,078 6,026 0.055623 0.028200 
VE - 20% HPV-16/18, 10% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 ref. ref. ref. ref. 0.071941 0.048573 
  Vaccination 68 78 94 120 9.561 386 ex. dom ex. dom dom 0.068057 0.046615 
  VIA 119 119 119 119 9.631 727 698 698 698 0.062716 0.030744 
  Vaccination & VIA 122 132 148 174 9.635 768 3,171 7,016 13,264 0.059414 0.029553 
VE, vaccine efficacy; VC, vaccine cost; dom, dominated; ex.dom, dominated by extension. VIA occurs at baseline, year five, and year 10 of the simulation 
a: per 1,000 women screened 
b: strategy become more cost-effective than  no active screening 
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Table 11.  continued… 
 
  Cost 2013 I$ Life 
Years 
ICER Cancer 
Incidence 
Cancer 
Death Strategy VC-5 VC-15 VC-31 VC-57 VC-5 VC-15 VC-31 VC-57 
Duration of immunity - 10 years 
VE - 80% HPV-16/18, 50% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 dom. ref. ref. ref. 0.071941 0.048573 
  Vaccination 58 68 84 110 9.589 ref.b 54 517 ex. dom 0.054398 0.038169 
  VIA 119 119 119 119 9.631 dom. ex. dom 847 698 0.062716 0.030744 
  Vaccination & VIA 115 125 141 167 9.652 906 906 1,021 2,243 0.048928 0.024770 
VE - 60% HPV-16/18, 30% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 dom. ref. ref. ref. 0.071941 0.048573 
  Vaccination 63 73 89 115 9.577 Ref b 301 ex. dom ex. dom 0.060959 0.042009 
  VIA 119 119 119 119 9.631 dom. ex. dom 698 698 0.062716 0.030744 
  Vaccination & VIA 118 128 144 170 9.645 819 819 1,808 3,682 0.053951 0.026918 
VE - 40% HPV-16/18, 20% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 dom. ref. ref. ref. 0.071941 0.048573 
  Vaccination 66 76 92 118 9.569 ref. ex. dom ex. dom ex. dom 0.065185 0.044523 
  VIA 119 119 119 119 9.631 ex. dom 698 698 698 0.062716 0.030744 
  Vaccination & VIA 120 130 146 172 9.640 769 1,301 3,139 6,127 0.057282 0.028364 
VE - 20% HPV-16/18, 10% HPV-Other 
  No screening/vaccination 66 66 66 66 9.555 ref. ref. ref. ref. 0.071941 0.048573 
  Vaccination 68 78 94 120 9.561 401 ex. dom ex. dom dom 0.068807 0.046689 
  VIA 119 119 119 119 9.631 725 698 698 698 0.062716 0.030744 
  Vaccination & VIA 122 132 148 174 9.635 798 3,232 7,127 13,457 0.060178 0.029629 
VE, vaccine efficacy; VC, vaccine cost; dom, dominated; ex.dom, dominated by extension. VIA occurs at baseline, year five, and year 10 of the simulation 
a: per 1,000 women screened 
b: strategy become more cost-effective than  no active screening 
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Table 12.  One-way sensitivity analyses, cost-effectiveness of cervical cancer prevention strategies 
in HIV+ Senegalese women 
 
 Incremental cost-effectiveness ratio (life expectancy) 
 VE – 80% HPV-16/18, 50% HPV-Other VE – 20% HPV-16/18, 10% HPV-Other 
Input variable Vaccination VIA 
Vaccination 
& VIA 
Vaccination VIA 
Vaccination 
& VIA 
Base case 498 (9.590) 866 (9.631) 985 (9.653) ex. dom (9.561) 698 (9.631) 7,016 (9.635) 
Death – other causes        
Minimum, 0.0050 305 (11.105) ex. dom (11.157) 740 (11.185) ex. dom (11.068) 555 (11.157) 5,317 (11.162) 
Maximum, 0.0200 753 (8.355) 968 (8.388) 1,392 (8.405) ex. dom (8.333) 872 (8.388) 9,213 (8.391) 
Discounting        
Minimum, 0 255 (11.643) ex. dom (11.699) 685 (11.729) ex. dom (11.603) 508 (11.699) 4,875 (11.705) 
Maximum, 0.05 711 (8.522) 967 (8.557) 1,324 (8.574) ex. dom (8.500) 852 (8.557) 8,850 (8.560) 
Initial parameterization, Normal         
Minimum, 27.89% 536 (9.588) 822 (9.631) 1,017 (9.652) ex. dom (9.561) 697 (9.631) 7,194 (9.635) 
Maximum, 41.83% 464 (9.592) 913 (9.631) 955 (9.653) ex. dom (9.562) 698 (9.631) 6,846 (9.636) 
VIA cost        
Minimum, I$2 499 (9.590) 642 (9.631) 985 (9.653) ex. dom (9.561) 577 (9.631) 7,015 (9.635) 
Maximum, I$8 497 (9.590) ex. dom (9.631) 1,053 (9.653) ex. dom (9.561) 818 (9.631) 7,016 (9.635) 
VIA screening uptake        
Minimum, 60% 498 (9.590) 738 (9.608) 742 (9.634) ex. dom (9.561) 581 (9.608) 5,699 (9.613) 
Base, 100% 498 (9.590) 866 (9.631) 985 (9.653) ex. dom (9.561) 698 (9.631) 7,016 (9.635) 
VIA sensitivity        
Minimum, 63% 498 (9.590) 930 (9.628) 978 (9.650) ex. dom (9.561) 724 (9.628) 6,959 (9.632) 
Maximum, 87% 498 (9.590) 814 (9.634) 994 (9.655) ex. dom (9.561) 675 (9.634) 7,077 (9.638) 
VIA specificity        
Minimum, 51% 498 (9.590) ex. dom (9.631) 1,381 (9.653) ex. dom (9.561) 1,086 (9.631) 7,026 (9.635) 
Maximum, 89% ex. dom (9.590) 309 (9.631) 974 (9.653) ex. dom (9.561) 309 (9.631) 7,005 (9.635) 
Retention in follow-up LEEP care       
Minimum, 60% 498 (9.590) 880 (9.629) 984 (9.651) ex. dom (9.561) 702 (9.629) 6,989 (9.634) 
Base, 100% 498 (9.590) 866 (9.631) 985 (9.653) ex. dom (9.561) 698 (9.631) 7,016 (9.635) 
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Table 12.  continued… 
 
 Incremental cost-effectiveness ratio (life expectancy) 
 VE – 80% HPV-16/18, 50% HPV-Other VE – 80% HPV-16/18, 50% HPV-Other 
Input variable Vaccination VIA 
Vaccination 
& VIA 
Vaccination VIA 
Vaccination 
& VIA 
Pre-cancer treatment effectiveness      
Minimum, 60% 498 (9.590) ex. dom (9.626) 1,008 (9.648) ex. dom (9.561) 772 (9.626) 6,920 (9.630) 
Maximum, 90% 498 (9.590) 800 (9.633) 997 (9.655) ex. dom (9.561) 666 (9.633) 7,067 (9.637) 
VE, vaccine efficacy; dom, dominated; ex.dom, dominated by extension. Duration of immunity set at 15 years. VIA was set to occur at baseline, year five, 
and year 10 of the simulation. Vaccine cost set to I$31.  
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Figure 1. Visual of the cervix 
 
 
Source: Herfs et al. 2012 [280] 
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Figure 2. Cervical clinical disease and classification schemes 
 
 
Source: Bratcher J, Palefsky J. 2008. Anogenital HVP Infection & Associated Neoplasia in HIV+ Men and 
Women. The PRN Notebook. 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
Figure 3. The natural history of cervical cancer 
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Figure 4. HPV type distributions among women with high-grade 
squamous intraepithelial lesions 
 
 
Source: Adapted from Clifford et al.[96] 
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Figure 5. Predicted cumulative probabilities for HIV+ and HIV- 
Senegalese women* 
 
 
 
 
 
*Note different x and y axis scaling between figures. 
 81 
 
 
 
 
 
 
*Note different x and y axis scaling between figures. 
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*Note different x and y axis scaling between figures. 
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Figure 6. Overview of natural history model states and transitions 
 
 
 
*For all non-death states women may continue to remain within a given state, in addition to 
transitioning to another state (depicted above). 
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Figure 7. Cost-effectiveness acceptability curve, cervical cancer screening among HIV+ women  
 
 
*The willingness-to-pay threshold for ‘very cost-effective’ strategies (I$1,050) is depicted in the vertical line for reference, with the upper bound 
for “cost effective” at I$3,150 (based on WHO criterion). 
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Figure 8. Overview of model states and transitions 
 
*For all non-death states women may continue to remain within a given state, in addition to 
transitioning to another state (depicted above). Transitions impacted by the vaccine are in bold, dash 
lines. 
 
 
 86 
Figure 9. Tornado plots displaying the impact of uncertainty in key 
input variables 
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